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Abstract	  
	  
Human	  herpes	  virus	  8	  (HHV8)	  is	  the	  aetiological	  agent	  of	  all	  forms	  of	  Kaposi’s	  sarcoma	  (KS).	  
Seven	  major	  subtypes	  (A,	  B,	  C,	  D,	  E,	  F,	  Z)	  based	  on	  genetic	  variability	  of	  open	  reading	  frame	  
(ORF)-­‐K1,	   have	   been	   identified.	   Numerous	   studies	   point	   to	   differing	   tumorigenic	   and	  
pathogenic	   properties	   of	   the	   HHV8	   subtypes.	   The	   study	   objective	   was	   to	   determine	   the	  
prevalence	  of	   the	  HHV8	  subtypes	   in	  a	  cohort	  of	   clinical	  and	  histologically	   confirmed	  KS	   in	  
Cape	  Town,	  South	  Africa,	  and	  analyse	  associations	  between	  the	  different	  subtypes,	  clinico-­‐
epidemiological	  forms	  and	  clinical	  presentation	  of	  KS.	  
The	   clinical	   data	   was	   prospectively	   collected	   and	   recorded	   on	   a	   body	   diagram	   and	   with	  
photographs.	  Demographic	  data	  was	  retrospectively	  collected	   from	  clinical	   records.	  Tissue	  
biopsies	  were	  taken	  for	  ORF-­‐K1	  subtyping.	  
Out	   of	   a	   cohort	   of	   103,	   eighty	   six	   patients	   were	   subtyped;	   81	   AIDS	   (aquired	   immune	  
deficiency	   syndrome)-­‐KS	   and	   5	   African	   endemic.	   Subtype	   A5	   (42/86)	   and	   B2	   (16/86)	  
predominated.	  B1,	  B3,	  A1	  and	  A4	  subtypes	  were	   identified	   in	  10/86,	  9/86,	  4/86	  and	  1/86	  
patients	   respectively.	   A5,	   B1,	   B2	   and	   B3	   were	   found	   in	   African	   blacks	   and	   individuals	   of	  
mixed	  ancestry,	  while	  subtypes	  A1	  and	  A4	  are	  found	  only	  in	  whites	  and	  individuals	  of	  mixed	  
ancestry.	  
Subtype	  A5	  was	  associated	  with	  >10	  KS	   lesions	  at	  presentation	   in	   the	  AIDS-­‐cohort	   (32/38,	  
p=0,050),	  but	  not	  in	  the	  African	  endemic	  patients	  (2/4,	  p=0,600).	  Subtypes	  A1	  and	  A4	  were	  
less	  likely	  to	  be	  associated	  with	  poor	  risk	  tumour	  extension	  (p=0,031)	  and	  A1	  was	  associated	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CHAPTER	  1:	  Literature	  review	  	  	  
Kaposi’s	  Sarcoma:	  Genetic	  subtypes	  and	  clinical	  correlation	  in	  a	  South	  African	  population	  
	  
Researcher:	  Thuraya	  Isaacs	  
Supervisor:	  Prof	  Gail	  Todd	  	  
Co-­‐supervisor:	  Prof	  Arieh	  Katz	  
	  
	  
Total	  word	  count:	  	  6192	  
	  
INTRODUCTION	  
Kaposi’s	  sarcoma	  (KS)	  is	  a	  multifocal	  proliferative	  disorder	  involving	  blood	  and	  lymphatic	  
vessels.	  The	  aetiology	  of	  KS	  has	  been	  elucidated	  in	  1994,	  and	  is	  due	  to	  KS-­‐associated	  herpes	  
virus	  also	  known	  as	  human	  herpes	  virus	  8	  (HHV8)	  [Chang	  et	  al.,	  1994].	  It	  is	  also	  the	  
aetiological	  agent	  of	  B-­‐cell	  primary	  effusion	  lymphoma	  (PEL)	  and	  multicentric	  Castleman	  
disease	  [Ablashi	  et	  al.,	  2002].	  KS	  is	  an	  AIDS-­‐defining	  disease	  and	  is	  the	  most	  common	  AIDS-­‐
related	  malignancy,	  moreover,	  it	  is	  one	  of	  the	  most	  common	  cancers	  in	  several	  sub-­‐Saharan	  
countries	  [Morris,	  2003;	  Wabinga	  et	  al.,	  1993].	  With	  the	  onset	  of	  the	  HIV	  pandemic,	  the	  
prevalence	  of	  Kaposi’s	  sarcoma	  (KS)	  in	  some	  areas	  of	  sub-­‐Saharan	  Africa	  has	  risen	  between	  
three	  and	  twenty	  fold	  [Parkin	  et	  al.,	  1999].	  	  
	  
Six	  major	  subtypes	  (A,	  B,	  C,	  D,	  E	  and	  F)	  and	  at	  least	  13	  different	  variants	  or	  clades	  based	  on	  
genetic	  variability	  of	  ORF-­‐K1	  gene	  sequences,	  have	  been	  identified	  [Zong	  et	  al.,	  2002].	  The	  
different	  subtypes	  have	  been	  shown	  to	  have	  variable	  penetrance	  in	  various	  population	  
groups	  and	  are	  distributed	  along	  broad	  geographic	  and	  ethnic	  lines,	  which	  may	  have	  arisen	  
through	  ancient	  human	  migrations	  [Hayward,	  1999;	  Hayward	  and	  Zong,	  2007;	  Zong	  et	  al.,	  
2002;	  Zong	  et	  al.,	  1999].	  Debate	  exists	  as	  to	  whether	  different	  genetic	  subtypes	  of	  HHV8	  
have	  different	  biologic	  and	  pathologic	  properties,	  which	  could	  potentially	  affect	  disease	  
prognosis	  and	  direct	  future	  therapies.	  This	  introduction	  reviews	  the	  relevant	  literature	  and	  
provides	  an	  overview	  of	  clinico-­‐epidemiological	  forms	  of	  KS,	  the	  genetic	  subtyping	  of	  HHV8,	  
the	  geographic	  distribution	  of	  subtypes,	  evolutionary	  advantage	  of	  HHV8,	  staging	  and	  an	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appraisal	  of	  the	  literature	  surrounding	  a	  possible	  association	  between	  the	  different	  genetic	  
subtypes	  of	  HHV8	  and	  pathogenicity	  of	  KS.	  	  
	  
CLINICO-­‐EPIDEMIOLOGIC	  VARIANTS	  	  
Clinically	  KS	  presents	  as	  patches,	  plaques	  and	  nodules	  of	  varying	  colour	  from	  skin	  coloured,	  
to	  red	  to	  purple	  to	  black/brown,	  it	  may	  present	  or	  be	  complicated	  by	  lymphoedema	  and	  
may	  be	  complicated	  by	  ulceration	  (Figures	  1-­‐5).	  There	  are	  four	  principal	  clinico-­‐
epidemiological	  variants	  of	  KS,	  namely	  classic	  KS,	  African	  endemic	  KS,	  iatrogenic	  KS	  and	  
AIDS-­‐KS.	  As	  originally	  described	  by	  Mauritz	  Kaposi,	  classic	  KS	  is	  mostly	  seen	  in	  elderly	  
Caucasian	  men,	  aged	  50-­‐60	  years,	  of	  Mediterranean	  or	  eastern	  European	  and	  Jewish	  origin	  
[Buonaguro	  et	  al.,	  2003].	  It	  is	  usually	  chronic	  and	  locally	  indolent,	  confined	  to	  the	  lower	  
extremities	  with	  a	  good	  prognosis.	  Iatrogenic	  KS	  has	  been	  observed	  following	  solid	  organ	  
transplantation,	  after	  prolonged	  exposure	  to	  immunosuppression	  including	  exposure	  to	  
immunosuppressive	  medication	  [Buonaguro	  et	  al.,	  2003;	  Penn,	  1983].	  The	  disease	  course	  
may	  be	  chronic	  or	  progressive.	  Spontaneous	  regression	  is	  observed	  in	  the	  majority	  of	  
patients	  with	  iatrogenic	  KS	  following	  discontinuation	  of	  immunosuppressive	  therapy.	  
African	  endemic	  KS	  has	  four	  clinical	  variants:	  1)	  benign	  nodular	  disease	  that	  resembles	  
classic	  KS	  and	  presents	  with	  indolent,	  localised	  cutaneous	  tumours,	  but	  affects	  younger	  men	  
(aged	  25-­‐40	  years)	  2)	  a	  locally	  aggressive	  form	  that	  mainly	  affects	  the	  extremities,	  with	  
fungating	  and	  exophytic	  growth,	  with	  a	  tendency	  to	  invade	  the	  surrounding	  tissues	  
including	  bone.	  3)	  a	  lymphadenopathic	  form	  predominantly	  seen	  in	  children	  (aged	  <15	  
years)	  with	  a	  poor	  prognosis	  and	  4)	  a	  florid	  form	  with	  widely	  disseminated	  disease	  and	  
visceral	  involvement	  [Buonaguro	  et	  al.,	  2003;	  Templeton,	  1981].	  AIDS-­‐related	  (epidemic)	  KS	  
was	  initially	  described	  as	  a	  fulminant,	  disseminated	  form	  of	  the	  disease	  in	  male	  
homosexuals,	  and	  was	  later	  found	  to	  be	  associated	  with	  AIDS.	  It	  presents	  with	  disseminated	  
cutaneous	  and	  visceral	  disease,	  and	  affects	  a	  younger	  population	  [Beral	  et	  al.,	  1990;	  Biggar	  
et	  al.,	  2000;	  Buonaguro	  et	  al.,	  2003;	  Dal	  Maso	  et	  al.,	  2009].	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Figure	  1.	  Nodular	  KS	  of	  the	  oral	  mucosa	  
	  
Figure	  2.	  Nodular	  KS	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Figure	  5.	  KS	  with	  lymphoedema	  
	  
AIDS	  KS	  
With	  the	  onset	  of	  the	  HIV	  pandemic,	  the	  prevalence	  of	  Kaposi’s	  sarcoma	  (KS)	  in	  some	  areas	  
of	  sub-­‐Saharan	  Africa	  has	  risen	  between	  three	  -­‐	  and	  twenty	  fold	  [Parkin	  et	  al.,	  1999].	  
In	  sub	  Saharan	  Africa,	  the	  AIDS	  epidemic	  has	  led	  to	  a	  dramatic	  increase	  in	  the	  incidence	  of	  
Kaposi’s	  sarcoma.	  In	  countries	  such	  as	  Uganda	  and	  Zimbabwe,	  the	  incidence	  of	  KS	  has	  
increased	  20	  fold	  to	  become	  the	  most	  common	  cancer	  in	  males,	  and	  the	  second	  most	  
common	  in	  women	  [Wabinga	  et	  al.,	  1993].	  A	  South	  African	  retrospective	  record	  review	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analysed	  the	  temporal	  trends	  in	  the	  incidence	  of	  KS	  in	  blacks	  in	  KwaZulu	  Natal,	  South	  Africa	  
over	  a	  period	  of	  23	  years	  (1983-­‐2006).	  Age	  standardized	  incidence	  rates	  increased	  from	  <1	  
per	  100,000	  in	  1990	  to	  15	  per	  100,000	  in	  2006.	  The	  age	  standardized	  incidence	  rates	  for	  KS	  
increased	  20-­‐fold	  in	  men	  and	  50-­‐fold	  in	  women	  [Mosam	  et	  al.,	  2009].	  Adult	  seroprevalence	  
rates	  of	  HHV8	  in	  South	  Africa	  amongst	  medical	  patients	  and	  patients	  with	  sexually	  
transmitted	  diseases	  in	  KwaZulu	  Natal	  increased	  with	  age,	  ranging	  from	  32%	  in	  age	  group	  
15-­‐34	  to	  63%	  among	  adults	  aged	  35-­‐69	  years	  [Wilkinson	  et	  al.,	  1999].	  	  
	  
STAGING	  AND	  CLASSIFICATION	  
In	  the	  literature,	  numerous	  classifications	  have	  been	  proposed	  but	  no	  universally	  accepted	  
classification	  system	  is	  available	  for	  KS.	  Some	  are	  classified	  by	  clinical	  parameters	  and	  others	  
by	  histological	  parameters.	  The	  first	  classification	  was	  in	  1971,	  when	  KS	  was	  first	  described	  
in	  Africa.	  Taylor	  et	  al.	  described	  three	  main	  categories	  (1)	  the	  nodular	  or	  benign	  form;	  (2)	  
the	  localized	  form	  characterized	  by	  exophytic	  or	  infiltrative	  growth	  patterns,	  which	  may	  
involve	  underlying	  bone;	  and	  (3)	  the	  generalized	  form	  which	  may	  be	  either	  the	  
lymphadenopathic	  childhood	  form	  or	  systemic	  disease	  with	  or	  without	  nodal	  involvement	  
[Taylor	  et	  al.,	  1971]	  (Table	  4).	  In	  1981,	  Kyalwaza	  proposed	  a	  new	  classification	  for	  African	  KS,	  
dividing	  it	  into	  indolent	  and	  aggressive	  disease:	  the	  indolent	  variety	  being	  divided	  into	  
nodular	  and	  plaque	  disease;	  and	  aggressive	  disease	  being	  divided	  into	  florid,	  
lymphadenopathic,	  infiltrative,	  visceral	  and	  bone	  disease.	  Klein	  in	  1982	  proposed	  yet	  
another	  classification	  namely	  into	  nodular,	  generalized	  lymphadenopathic	  and	  locally	  
aggressive	  types	  [Cottoni	  F,	  1996]	  (Table	  1).	  	  
	  
Table	  1.	  Kaposi’s	  sarcoma	  clinical	  classification	  prior	  to	  AIDS	  epidemic.	  Adapted	  from	  
Cottoni,	  1996	  
Taylor	  et	  al	  (1971)	   Kyalwaza	  (1981)	   Klein	  (1982)	  
Nodular	  disease	  (Benign)	   Indolent	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Generalised	  
Lymphadenopathic	  
Systemic	  with	  or	  without	  
nodal	  involvement	  
	   Locally	  aggressive	  
type	  
	  
With	  onset	  of	  AIDS-­‐KS	  and	  the	  presentation	  of	  more	  disseminated	  disease,	  a	  newer	  
classification	  was	  proposed	  based	  on	  clinical	  findings	  that	  subdivided	  the	  disseminated	  
disease	  seen	  in	  HIV	  infected	  homosexual	  males.	  This	  four-­‐stage	  classification	  was	  based	  on	  
the	  clinical	  appearance	  of	  tumours	  and	  on	  systemic	  involvement.	  It	  took	  into	  account	  
parameters	  such	  as	  skin	  lesions	  (localized,	  generalized,	  locally	  aggressive)	  with	  generalized	  
defined	  as	  more	  than	  upper	  or	  lower	  extremity	  involvement,	  lymph	  node	  involvement,	  
visceral	  involvement,	  and	  presence	  or	  absence	  of	  systemic	  signs	  (A	  or	  B	  symptoms	  
respectively)	  [Krigel	  et	  al.,	  1983].	  Stage	  1	  is	  defined	  as	  cutaneous,	  locally	  indolent	  disease;	  
stage	  2	  as	  cutaneous,	  locally	  aggressive	  with	  or	  without	  lymphadenopathy.	  Stage	  3	  is	  
generalized	  mucocutaneous	  with	  or	  without	  lymphadenopathy;	  and	  stage	  4	  is	  visceral	  
disease.	  Mitsuyaso	  and	  Groopman	  proposed	  a	  new	  four-­‐stage	  classification	  for	  AIDS-­‐KS	  in	  
1984	  (Table	  2).	  Schwartz	  divided	  KS	  into	  four	  stages:	  localized	  nodular,	  localized	  aggressive,	  
generalised	  lymphadenopathic	  and	  disseminated	  visceral	  [Schwartz	  RA,	  1984]	  (Table	  2).	  
Alessi	  et	  al	  divided	  KS	  into	  three	  classes.	  This	  took	  into	  account	  the	  extent	  of	  cutaneous	  
involvement,	  and	  the	  presence	  of	  lymph	  node,	  mucosal,	  and	  visceral	  involvement	  as	  well	  as	  
the	  presence	  or	  absence	  of	  opportunistic	  infections	  (referred	  to	  as	  A	  or	  B)(Table	  2).	  
Problems	  with	  these	  former	  classifications	  are	  that	  there	  was	  an	  absence	  of	  uniform	  
characteristics;	  and	  that	  the	  meaning	  of	  clinical	  parameters	  used,	  such	  as	  indolent	  and	  
aggressive,	  have	  not	  been	  clearly	  defined	  [Cottoni	  F,	  1996].	  Cottoni	  et	  al.	  proposed	  a	  new	  
classification	  dividing	  KS	  into	  four	  stages	  which	  included	  localized,	  generalized,	  aggressive	  
and	  noncutaneous	  disease	  based	  on	  lesion	  count,	  body	  surface	  area	  and	  visceral	  
involvement	  [Cottoni	  F,	  1996]	  (Table	  2).	  	  
	  
Table	  2.	  Classification	  of	  AIDS-­‐KS.	  Adapted	  from	  Cottoni,	  1996	  




Schwartz	  (1984)	   Alessi	  et	  al.	  
(1988)	  
Cottoni	  (1996)	  








1	   Cutaneous,	  
locally	  indolent	  
Limited	  cutaneous	  	  
(<10	  lesions	  in	  one	  
anatomic	  area)	  
Localized	  nodular	  
(>15	  lesions	  or	  
restricted	  to	  one	  
Cutaneous	  (<5	  
lesions,	  or	  one	  
anatomic	  area,	  
Localised	  
(<10	  lesions,	  or	  
body	  surface	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bilateral	  anatomic	  
site	  and	  few,	  if	  












(>10	  lesions	  or	  







cutaneous	  lesions)	  	  
Cutaneous	  with	  
>5	  lesions	  >1	  
anatomic	  area	  
+/-­‐	  mucosa	  +/-­‐	  
gastrointestinal	  
Generalised	  
(>10	  lesions,	  or	  
body	  surface	  
area	  >	  9%	  
3	   Generalised	  
mucocutaneo































KS:	  widespread	  KS,	  
with	  involvement	  
of	  multiple	  visceral	  
organs	  	  
	   Noncutaneous:	  
absence	  of	  
skin	  lesions	  
	   	   	   	   	   	  
A	   Asymptomatic	   No	  systemic	  signs	  
and	  symptoms	  
	   Opportunistic	  
infections	  
absent	  and	  CD4	  
<500	  
	  








Weight	  loss	  >10	  %	  
body	  weight	  
Fever	  >37,8C	  for	  >2	  
weeks-­‐	  not	  due	  
to	  identifiable	  
infection	  	  





The	  AIDS	  Clinical	  Trials	  Group	  (ACTG)	  oncology	  committee	  sought	  to	  develop	  “easily	  applied	  
and	  unambiguous	  criteria	  for	  evaluation	  of	  patients	  with	  KS	  “	  in	  order	  to	  evaluate	  efficacy	  of	  
therapeutic	  regimes	  due	  to	  the	  lack	  of	  uniform	  criteria	  to	  document	  disease	  extent,	  tumour	  
stage	  and	  treatment	  response.	  This	  was	  initially	  developed	  to	  evaluate	  and	  compare	  
therapeutic	  efficacy	  in	  KS	  patients	  enrolled	  on	  ACTG	  therapeutic	  trials,	  but	  was	  also	  
intended	  for	  the	  evaluation	  and	  comparison	  of	  efficacy	  of	  various	  regimens,	  as	  well	  as	  
correlating	  features	  of	  the	  disease	  with	  prognosis	  that	  would	  facilitate	  the	  identification	  of	  
optimal	  therapeutic	  strategies.	  It	  identified	  clinical	  and	  immunological	  parameters	  that	  are	  
associated	  with	  survival	  (Table	  3).	  The	  staging	  system	  classified	  patients	  into	  good	  risk	  or	  
poor	  risk	  groups	  according	  to	  the	  TIS	  (tumour,	  immune	  status,	  systemic	  illness)	  variables;	  
namely	  extent	  of	  tumour	  (T0:	  confined	  to	  the	  skin	  and/or	  lymph	  nodes	  and/or	  non	  nodular	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oral	  KS	  vs	  T1:	  extensive	  oral	  KS	  including	  nodular	  oral	  KS,	  tumour	  associated	  oedema	  or	  
ulceration,	  gastrointestinal	  KS,	  KS	  in	  other	  non-­‐nodal	  viscera)	  ,	  CD4	  counts	  (I0:>200	  
cells/microliter	  vs	  I1:	  <200	  cells/microlitre),	  and	  concomitant	  systemic	  illness	  (S0:	  absence	  of	  
B	  symptoms,	  opportunistic	  infections	  vs	  S1:	  presence	  of	  B	  symptoms,	  opportunistic	  
infections)	  [Krown	  et	  al.,	  1989].	  	  
	  
A	  study	  of	  294	  consecutively	  enrolled	  patients	  in	  8	  ACTG	  therapeutic	  trials,	  sought	  to	  
prospectively	  validate	  the	  ACTG	  staging	  classification	  for	  AIDS-­‐KS.	  They	  were	  staged	  
prospectively	  according	  to	  TIS	  variables	  and	  were	  observed	  for	  survival.	  Univariate	  and	  
multivariate	  analyses	  were	  done	  to	  evaluate	  the	  association	  between	  TIS	  variables	  and	  
survival.	  Survival	  was	  significantly	  lower	  in	  patients	  in	  poor	  risk	  categories	  of	  each	  of	  the	  TIS	  
variables.	  Median	  survival	  for	  T0	  and	  T1	  were	  27	  and	  15	  months	  (p=0,001);	  for	  I0	  and	  I1	  
were	  40	  and	  13	  months	  (p<0,001);	  and	  for	  S0	  and	  S1	  were	  22	  and	  16	  months	  respectively	  
(p=0,04).	  Multivariate	  analysis	  showed	  that	  immune	  system	  impairment	  (I)	  was	  the	  most	  
important	  predictor	  of	  survival,	  but	  also	  showed	  that	  in	  patients	  with	  a	  high	  CD4	  count	  
whose	  immune	  system	  was	  least	  impaired,	  tumour	  stage	  (T)	  provided	  significant	  predictive	  
value	  [Krown	  et	  al.,	  1997].	  	  
	  
Refined	  Cox	  models	  using	  a	  lower	  CD4	  count	  (150	  cell/microlitre)	  provided	  better	  
discrimination	  between	  prognostic	  groups	  than	  the	  published	  cutoff	  of	  200	  cells/microlitre	  
[Krown	  et	  al.,	  1997].	  Limitations	  of	  this	  internal	  validation	  of	  the	  ACTG	  classification	  is	  that	  it	  
was	  conducted	  within	  patients	  enrolled	  in	  therapeutic	  trials;	  hence	  may	  have	  excluded	  
individuals	  at	  both	  ends	  of	  the	  severity	  spectrum	  with	  severe	  end	  organ	  damage	  or	  minimal	  
disease	  not	  thought	  to	  warrant	  systemic	  therapy;	  and	  may	  not	  be	  generalizable.	  
	  
Table	  3:	  The	  AIDS	  Clinical	  Trials	  Group	  criteria	  
	   Good	  Risk	  (0)	   Poor	  risk	  (1)	  
Tumour	  (T)	   Confined	  to	  skin	  and/or	  lymph	  
nodes	  
Minimal	  oral	  disease	  (non-­‐
nodular)	  
Oedema/ulceration	  
Extensive	  oral	  KS	  
Visceral	  KS	  
Immune	  status	  (I)	   CD4	  <150	   CD4	  >150	  
Systemic	  illness	  (S)	   No	  thrush	  or	  opportunistic	  
infections	  
Thrush	  or	  opportunistic	  infections	  
B	  symptoms	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No	  B	  symptoms	  
Karnofsky	  score	  >70	  
Karnofsky	  score	  <70	  
Other	  HIV	  related	  disease	  
Karnofsky	  score:	  See	  Appendix	  
Nasti	  sought	  to	  externally	  validate	  the	  ACTG	  staging	  system	  as	  none	  of	  the	  prior	  studies	  
were	  conducted	  in	  the	  era	  of	  highly	  active	  anti-­‐retroviral	  therapy	  (HAART).	  They	  concluded	  
that	  CD4	  level	  did	  not	  provide	  prognostic	  information	  in	  the	  post-­‐HAART	  era.	  Only	  the	  
combination	  of	  poor	  tumour	  stage	  (T1)	  and	  poor	  systemic	  disease	  (S1)	  risk,	  identified	  
patients	  with	  unfavourable	  prognosis.	  The	  three	  year	  survival	  rates	  for	  T1S1	  was	  53%,	  which	  
was	  significantly	  lower	  compared	  to	  T0S0	  (88%),	  T1S0	  (80%)	  and	  T0S1	  (81%).	  Two	  different	  
risk	  categories	  were	  proposed:	  good	  risk	  (T0S0,	  T1S0,	  T0S1)	  and	  poor	  risk	  (T1S1).	  Patients	  
with	  T1	  and	  pulmonary	  disease	  (T1p1)	  were	  also	  identified	  as	  having	  a	  poor	  prognosis	  [Nasti	  
et	  al.,	  2003b].	  	  
	  
A	  retrospective	  study	  in	  a	  resource	  limited	  setting	  in	  Uganda	  sought	  to	  evaluate	  ACTG	  
staging	  criteria	  as	  predictive	  of	  overall	  survival	  among	  Ugandan	  patients	  with	  AIDS-­‐KS.	  The	  
reason	  for	  this	  external	  validation	  was	  that	  it	  had	  been	  validated	  in	  the	  United	  States	  and	  
Europe,	  but	  not	  in	  resource	  limited	  settings.	  Multivariate	  analysis	  showed	  that	  tumour	  
extent	  (HR	  4,33;	  p	  <0,001)	  and	  systemic	  involvement	  (HR	  1,63;	  p<0,01)	  was	  associated	  with	  
survival.	  Immune	  status	  (CD4	  count)	  was	  not	  (HR	  1,25;	  p=0,52)	  [Okuku,	  2012].	  	  This	  confirms	  
findings	  of	  Nasti	  et	  al	  [Nasti	  et	  al.,	  2003a;	  Nasti	  et	  al.,	  2003b].	  	  
	  
A	  newer	  prognostic	  index	  for	  AIDS-­‐KS	  in	  the	  era	  of	  HAART	  was	  proposed	  in	  2006	  to	  predict	  
survival	  in	  KS.	  It	  was	  developed	  as	  a	  simple	  model	  to	  predict	  survival	  based	  on	  presenting	  
features	  at	  the	  time	  of	  diagnosis	  of	  KS;	  and	  to	  aid	  in	  planning	  and	  evolution	  of	  trials	  and	  
treatments.	  Variables	  included	  ACTG	  TIS	  staging;	  age	  as	  a	  categorical	  variable,	  and	  KS	  as	  first	  
AIDS-­‐defining	  disease.	  Univariate	  and	  multivariate	  analysis	  was	  done	  to	  identify	  covariates	  
predictive	  of	  overall	  survival	  and	  this	  model	  was	  externally	  validated	  with	  an	  independent	  
data	  set	  of	  KS	  patients.	  In	  this	  prospective	  cohort	  study,	  the	  authors	  identified	  and	  validated	  
four	  prognostic	  factors	  that	  could	  be	  combined	  in	  a	  calculation	  to	  produce	  a	  prognostic	  
score	  of	  0	  to	  15	  based	  on	  the	  clinical	  characteristics	  at	  the	  time	  of	  KS	  diagnosis.	  Having	  KS	  as	  
the	  first	  AIDS	  defining	  illness,	  and	  an	  increasing	  CD4	  count	  improved	  prognosis	  (in	  
agreement	  with	  Krown	  et	  al.)	  while	  age	  more	  than	  50	  years	  old	  and	  having	  concomitant	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AIDS	  associated	  illness	  conveyed	  a	  poor	  prognosis	  [Stebbing	  et	  al.,	  2006].	  Prognostic	  scores	  
of	  0,	  5,	  10	  and	  15	  conferred	  a	  probability	  of	  survival	  at	  1-­‐year	  of	  0,993,	  0,967,	  0,834	  and	  
0,378;	  and	  a	  5	  year-­‐probability	  of	  survival	  of	  0,984,	  0,918,	  0,631	  and	  0,084	  respectively	  
[Stebbing	  et	  al.,	  2006].	  	  
	  
The	  ACTG	  and	  modified	  ACTG	  are	  still	  the	  most	  widely	  used	  prognostic	  indicators	  for	  KS	  in	  
the	  published	  literature.	  Advantages	  of	  using	  this	  classification	  system	  is	  that	  it	  has	  been	  
validated	  internally	  in	  the	  pre-­‐HAART	  era;	  but	  it	  has	  also	  been	  externally	  validated	  in	  both	  
Europe	  and	  in	  resource	  limited	  settings.	  Although	  the	  new	  prognostic	  index	  by	  Stebbing	  has	  
been	  externally	  validated	  in	  the	  post-­‐HAART	  era;	  it	  has	  not	  been	  evaluated	  in	  resource	  poor	  
settings	  and	  hence	  may	  not	  be	  generalizable	  to	  our	  setting.	  It	  has	  also	  not	  been	  widely	  used	  
even	  in	  the	  current	  literature.	  For	  this	  reason	  the	  modified	  ACTG	  system	  proposed	  by	  Nasti	  




HHV8	  is	  found	  consistently	  in	  all	  KS	  lesions	  of	  classic,	  endemic,	  AIDS-­‐KS,	  and	  iatrogenic	  KS	  
[Zong	  et	  al.,	  1999].	  HHV8	  is	  a	  gamma	  2	  herpes	  virus	  (family	  Herpesviridae,	  subfamily	  
Gammaherpesvirinae,	  genus	  Rhadinovirus),	  that	  is	  most	  similar	  in	  structure	  and	  gene	  
content	  to	  Herpesvirus	  saimiri	  (HVS)	  [Albrecht	  et	  al.,	  1992;	  Hayward,	  1999].	  The	  HHV8	  
genome	  harbours	  many	  genes	  that	  encode	  for	  novel	  proteins	  that	  are	  not	  found	  in	  other	  
human	  herpesviruses.	  Many	  of	  these	  genes	  represent	  divergent	  viral	  homologs	  of	  human	  
cellular	  oncogenes	  that	  were	  pirated	  by	  the	  virus,	  including	  viral	  interleukin-­‐6	  (vIL6),	  viral	  
interleukin-­‐8	  (vIL-­‐8)	  receptor,	  macrophage	  inflammatory	  protein	  (MIP),	  and	  anti-­‐apoptotic	  
proteins	  of	  the	  bcl-­‐2	  family	  [Hayward,	  1999;	  McGeoch	  and	  Davison,	  1999].	  These	  are	  
involved	  in	  activation	  of	  intracellular	  signaling	  pathways	  which	  result	  in	  a	  hyper-­‐
inflammatory	  state,	  angiogenesis	  and	  transformation	  of	  endothelial	  cells,	  thereby	  
contributing	  to	  tumour	  formation	  [Wood	  and	  Feller,	  2008].	  
	  
HHV8	  displays	  a	  latent	  and	  a	  lytic	  phase.	  The	  latent	  phase	  contributes	  to	  immune	  evasion	  
and	  to	  the	  establishment	  of	  persistent	  viral	  infection.	  The	  major	  latent	  viral	  proteins	  include	  
latency-­‐associated	  nuclear	  antigen	  (LANA1),	  viral	  cyclin	  (v-­‐cyc),	  and	  the	  viral	  Fas-­‐associated	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death	  domain	  interleukin-­‐1B	  converting	  enzyme	  inhibitory	  protein	  (vFLIP).	  Viral	  G-­‐protein	  
coupled	  receptor	  (vGPCR)	  and	  vIL-­‐6	  are	  lytic-­‐phase	  proteins	  [Wood	  and	  Feller,	  2008].	  	  
	  
LANA1	  is	  essential	  to	  maintain	  latency	  and	  may	  have	  a	  role	  in	  immune	  evasion.	  LANA1	  also	  
inhibits	  the	  tumor	  suppressors	  p53	  and	  retinoblastoma	  (Rb).	  This	  results	  in	  impaired	  
apoptosis	  and	  activation	  of	  genes	  involved	  in	  angiogenesis,	  cell	  proliferation,	  and	  survival.	  
vFLIP	  has	  been	  associated	  with	  cell	  survival,	  morphologic	  change,	  and	  inflammatory	  
activation.	  	  
Of	  the	  lytic	  phase	  proteins,	  vGPCR	  has	  the	  capacity	  to	  transform	  endothelial	  cells	  by	  
promoting	  their	  uncontrolled	  proliferation	  and	  by	  inhibition	  of	  apoptosis.	  Other	  viral	  lytic	  
oncogenes,	  such	  as	  vIL-­‐6,	  may	  also	  play	  a	  role	  in	  HHV8	  mediated	  cell	  cycle	  dysregulation;	  
however,	  their	  role	  has	  not	  yet	  been	  defined	  [Sunil	  et	  al.,	  2010].	  	  
	  
HHV8	  GENOME	  	  
HHV8	  is	  a	  double-­‐stranded	  (ds)	  DNA	  virus.	  Whereas	  the	  HHV8	  genome	  is	  circular	  in	  the	  
nucleus	  of	  latently	  infected	  cells;	  it	  is	  packaged	  into	  infectious	  viruses	  in	  a	  linear	  
configuration.	  The	  HHV8	  genome	  is	  mostly	  highly	  conserved,	  except	  for	  the	  two	  
hypervariable	  regions	  on	  the	  extreme	  left	  hand	  side	  (LHS)(ORF-­‐K1)	  and	  right	  hand	  side	  
(RHS)(TMP/	  K15)	  of	  the	  genome,	  which	  have	  been	  used	  as	  the	  basis	  for	  genetic	  subtyping.	  
ORF-­‐K1	  is	  also	  called	  variable	  ITAM-­‐containing	  protein	  (VIP)	  and	  ORF-­‐K15	  is	  also	  called	  latent	  
membrane	  protein	  (LMP)	  or	  latency-­‐associated	  membrane	  protein	  (LAMP).The	  central	  
constant	  segment	  lies	  between	  these	  two	  hypervariable	  regions	  (Figure	  6)	  [Zong	  et	  al.,	  
1999].	  
	  
Figure	  6.	  Diagrammatic	  representation	  of	  HHV8	  genome	  and	  analysed	  loci	  of	  Hayward	  and	  Zong	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ORF-­‐K1	  encodes	  a	  transmembrane	  glycoprotein	  of	  46	  kD	  on	  the	  extreme	  LHS	  of	  the	  genome	  
that	  shares	  homology	  with	  receptors	  of	  the	  human	  immunoglobulin	  superfamily.	  ORF-­‐K1	  
functions	  as	  a	  tyrosine	  kinase	  signaling	  protein;	  it	  has	  anti-­‐apoptotic	  properties	  and	  can	  
mimic	  or	  block	  activation	  of	  B-­‐cell	  receptors	  and	  may	  play	  a	  role	  in	  establishing	  clinical	  
latency	  [Hayward	  and	  Zong,	  2007].	  The	  ORF-­‐K1	  glycoprotein	  is	  composed	  of	  three	  domains:	  
the	  extracellular,	  the	  transmembrane	  and	  the	  intracellular	  domain.	  ORF-­‐K1	  shows	  the	  
highest	  variability	  within	  its	  nucleotide	  sequences	  as	  compared	  to	  other	  regions	  in	  the	  
genome.	  The	  extracellular	  domain	  is	  the	  most	  variable	  region	  in	  the	  protein,	  consisting	  of	  
two	  hypervariable	  regions,	  VR1	  and	  VR2,	  with	  sequence	  analysis	  thereof	  demonstrating	  up	  
to	  85%	  and	  60%	  divergence	  at	  the	  nucleotide	  and	  amino	  acid	  levels	  respectively.	  Analysis	  of	  
these	  hypervariable	  regions	  of	  ORF-­‐K1	  has	  been	  used	  as	  the	  basis	  of	  HHV8	  genetic	  subtyping	  
[Zong	  et	  al.,	  1999].	  	  	  
	  
The	  central	  constant	  region	  of	  the	  genome	  includes	  10	  well-­‐characterised	  internal	  	  loci	  that	  
have	  been	  PCR	  sequenced	  by	  Hayward	  and	  Zong	  including	  ORF-­‐26,	  T0.7,	  LANA,	  and	  UPS75	  
[Hayward	  and	  Zong,	  2007].	  
Apart	  from	  LANA1	  the	  functional	  significance	  of	  the	  rest	  of	  the	  loci	  analysed	  have	  not	  been	  
defined.	  
Unlike	  the	  hypervariability	  of	  ORF-­‐K1	  and	  TMP/K15	  genes,	  the	  level	  of	  variability	  at	  the	  
constant	  region	  is	  much	  smaller	  with	  only	  1	  to	  5	  %	  nucleotide	  differences,	  and	  hence	  they	  
rarely	  have	  impact	  on	  primary	  protein	  structure	  and	  rarely	  produce	  amino	  acid	  changes	  
[Hayward	  and	  Zong,	  2007;	  Zong	  et	  al.,	  2002;	  Poole	  et	  al.,	  1999]].	  The	  constant	  region	  loci	  
can	  be	  classified	  into	  distinctive	  ORF-­‐K1	  linked	  patterns.	  Much	  greater	  diversity	  and	  
variability	  is	  found	  within	  the	  constant	  region	  of	  samples	  from	  sub-­‐Saharan	  Africa;	  the	  
significance	  of	  which	  has	  not	  been	  studied	  [Hayward	  and	  Zong,	  2007].	  At	  the	  T0.7	  locus,	  
there	  are	  9	  distinct	  subtypes	  defined	  (A/C,	  F,	  G,	  J,	  K,	  B,	  Q,	  R,	  N).	  Of	  these,	  subtypes	  B,	  Q,	  R	  
and	  N	  are	  found	  exclusively	  within	  sub-­‐Saharan	  Africa.	  The	  level	  of	  variability	  in	  Q,	  R	  and	  N	  
are	  more	  highly	  diverged	  from	  the	  Eurasian	  A/C	  subtypes.	  For	  example,	  subtype	  Q	  differs	  
from	  Eurasian	  A/C	  by	  16%	  nucleotide	  variability	  [Hayward	  and	  Zong,	  2007;	  Zong	  et	  al.,	  2002;	  
Poole	  et	  al.,	  1999].	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The	  TMP/	  K15	  gene	  on	  the	  extreme	  RHS	  of	  the	  genome	  falls	  into	  three	  allelic	  subtypes	  
referred	  to	  as	  P	  (prototype)	  and	  M	  (minor);	  and	  a	  newly	  recognised	  novel	  N	  subtype.	  The	  P	  
allele	  is	  the	  predominant	  subtype	  and	  was	  found	  in	  46/66	  genomes	  tested	  and	  the	  TMP-­‐M	  
allele	  was	  found	  in	  20/66	  of	  genomes	  [Hayward,	  1999;	  Poole	  et	  al.,	  1999].	  The	  functional	  
significance	  of	  these	  subtypes	  is	  not	  known.	  
	  
	  
FUNCTIONAL	  SIGNIFICANCE	  OF	  ORF-­‐K1	  	  
ORF-­‐K1	  and	  ORF-­‐K15	  are	  the	  positional	  analogues	  (in	  the	  same	  position	  in	  the	  genome)	  of	  
key	  latent	  transforming	  membrane	  proteins	  at	  the	  LHS	  and	  RHS	  of	  the	  genomes	  of	  Epstein-­‐	  
Barr	  virus	  (EBV),	  namely	  LMP1	  and	  LMP2,	  and	  Herpesvirus	  saimiri	  (HVS),	  namely	  STP	  and	  
TIP.	  These	  membrane	  proteins,	  LMP1	  and	  STP,	  produce	  proliferative	  signals	  in	  B	  and	  T-­‐cells;	  
and	  LMP1	  and	  TIP	  block	  B-­‐cell	  and	  T-­‐cell	  receptor	  signaling	  needed	  to	  reactivate	  the	  lytic	  
cycle	  [Hayward,	  1999].	  ORF-­‐K1	  of	  HHV8	  has	  been	  shown	  to	  immortalize	  T-­‐cells	  and	  cause	  
tumorigenesis	  to	  an	  HVS	  genome	  that	  has	  been	  depleted	  of	  the	  STP	  gene	  [Lee,	  1998].	  ORF-­‐
K1	  contains	  tyrosine	  kinase	  interaction	  motifs	  that	  resemble	  the	  immunoreceptor	  tyrosine	  
based	  activator	  motif	  (ITAM)	  found	  in	  B-­‐cell,	  T-­‐cell	  and	  FcR	  receptors.	  Hence	  ORF-­‐K1	  may	  
functionally	  substitute	  for	  the	  ITAMS	  of	  B-­‐cells	  and	  T-­‐cells	  [Hayward,	  1999].	  	  
	  
ORF-­‐K1	  encodes	  for	  a	  protein	  (K1/	  VIP)	  that	  is	  involved	  in	  cellular	  transformation.	  This	  
transforming	  activity	  is	  via	  the	  phophatidylinositol	  3-­‐kinase	  (PI3K)/	  protein	  kinase	  B	  (Akt)/	  
mechanistic	  target	  of	  rapamycin	  (mTOR)	  pathway.	  K1	  deleted	  viral	  cells	  showed	  decreased	  
phosphorylation	  and	  activation	  of	  Akt	  kinase;	  and	  hence	  decreased	  	  viral	  lytic	  replication	  




Zong	  et	  al.	  initially	  carried	  out	  PCR	  sequencing	  of	  3	  small	  segments	  of	  the	  ORF-­‐26	  and	  ORF-­‐
75	  genes,	  from	  12	  KS	  specimens	  [Zong	  et	  al.,	  2007b].	  These	  sequences	  fell	  into	  3	  distinct	  
patterns,	  and	  were	  used	  to	  define	  3	  subtypes	  (A,	  B	  and	  C).	  The	  nucleotide	  variability	  
between	  the	  subtypes	  was	  low	  between	  1,0%	  and	  1,5%,	  with	  less	  than	  0,1	  %	  variability	  
within	  each	  group.	  The	  same	  authors	  analysed	  the	  hypervariable	  ORF-­‐K1	  gene,	  which	  shows	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the	  highest	  level	  of	  variability	  in	  the	  HHV8	  genome,	  and	  subsequent	  genetic	  subtyping	  has	  
been	  based	  on	  ORF-­‐K1.	  
	  
More	  recently,	  Hayward	  and	  Zong	  combined	  the	  analysis	  of	  three	  regions,	  the	  LHS	  side	  ORF-­‐
K1,	  the	  central	  constant	  segment	  loci	  and	  the	  RHS	  TMP	  allele,	  and	  have	  proposed	  a	  new	  




ORF-­‐K1	  SUBTYPES	  	  
Different	  HHV8	  strains	  have	  been	  defined	  by	  Hayward	  et	  al.	  and	  most	  subsequent	  authors	  
as	  falling	  into	  distinct	  subgroups	  based	  on	  a	  system	  of	  PCR	  DNA	  sequence	  analysis	  of	  the	  
ORF-­‐K1	  gene	  [Hayward	  et	  al.,	  1999].	  Variabilities	  in	  nucleotide	  and	  amino	  acid	  sequences	  
were	  calculated.	  Zong	  identified	  amino	  acid	  substitutions	  at	  a	  total	  of	  62%	  of	  the	  289	  amino	  
acid	  positions	  amongst	  60	  different	  tumour	  samples	  from	  the	  United	  States,	  Central	  Africa,	  
Saudi	  Arabia,	  Taiwan	  and	  New	  Zealand.	  Initially	  4	  major	  subtypes	  (A,	  B,	  C,	  and	  D)	  and	  13	  
distinct	  variants	  or	  clades	  were	  defined;	  of	  which	  A	  and	  B	  differed	  by	  30%	  (varied	  by	  85	  
amino	  acids);	  and	  A	  and	  C	  differed	  from	  each	  other	  by	  15%	  (varied	  by	  39	  amino	  acids)	  [Zong	  
et	  al.,	  1999].	  B	  subtype	  predominated	  in	  KS	  patients	  from	  Africa	  or	  of	  African	  heritage.	  D	  
subtypes	  were	  found	  only	  in	  classic	  KS	  patients	  of	  Pacific	  island	  heritage.	  C	  subtypes	  were	  
found	  predominantly	  in	  classic	  KS,	  iatrogenic	  KS	  and	  AIDS-­‐KS	  in	  the	  Middle	  East	  and	  Asia,	  
while	  three	  variants	  A1,	  A4	  and	  C3	  predominated	  within	  the	  United	  States	  (US)	  AIDS-­‐KS	  
samples	  [Hayward	  and	  Zong,	  2007;	  Zong	  et	  al.,	  1999;	  Zong	  et	  al.,	  2002].	  	  
	  
To	  date,	  six	  major	  subtypes	  (A,	  B,	  C,	  D,	  E,	  and	  F)	  and	  numerous	  minor	  variants	  or	  clades	  
based	  on	  genetic	  variability	  of	  the	  ORF-­‐K1	  gene	  sequences,	  have	  been	  identified	  with	  
variable	  penetrance	  in	  different	  population	  groups,	  and	  are	  distributed	  along	  broad	  
geographic	  and	  ethnic	  lines	  [Hayward,	  1999;	  Zong	  et	  al.,	  2002;	  Zong	  et	  al.,	  1999]	  (Figure	  7).	  
In	  sub-­‐Saharan	  Africa	  the	  B	  and	  A5	  subtypes	  have	  been	  found	  to	  predominate	  in	  studies	  of	  
tissue	  taken	  from	  KS	  patients	  [Cook	  et	  al.,	  1999;	  Fouchard	  et	  al.,	  2000;	  Hayward,	  1999;	  
Kajumbula	  et	  al.,	  2006;	  Lacoste	  et	  al.,	  2000;	  Meng	  et	  al.,	  1999;	  Treurnicht	  et	  al.,	  2002;	  White	  
et	  al.,	  2008;	  Zong	  et	  al.,	  2002;	  Zong	  et	  al.,	  1999;	  Tornesello	  et	  al.,	  2010;	  Olp	  et	  al.,	  2015;	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Kakoola	  et	  al.,	  2001].	  They	  have	  also	  predominated	  in	  sub-­‐Saharan	  Africa	  blood	  samples	  
from	  KS	  and	  non-­‐KS	  patients	  [Kajumbula	  et	  al.,	  2006;	  Meng	  et	  al.,	  1999;	  Cook	  et	  al.,	  1999]	  
and	  buccal	  swabs	  from	  patients	  without	  KS	  [Olp	  et	  al.,	  2013].	  A	  and	  C	  subtypes	  are	  found	  in	  
Caucasian	  KS	  patients	  throughout	  Europe,	  the	  United	  States,	  the	  Mediterranean	  basin	  the	  
Middle	  East	  and	  Asia	  [Cook	  et	  al.,	  1999;	  Zong	  et	  al.,	  1999],	  and	  D	  in	  the	  Pacific	  Islands	  and	  
Taiwan	  [Zhang	  et	  al.,	  2008;	  Zong	  et	  al.,	  1999].	  In	  Brazil	  there	  is	  a	  53%	  prevalence	  of	  subtype	  
E	  in	  Brazilian	  Indians,	  but	  the	  study	  was	  done	  on	  individuals	  without	  KS	  and	  therefore	  any	  
association	  between	  subtype	  E	  and	  KS	  development	  remains	  to	  be	  studied	  [Biggar	  et	  al.,	  






Figure	  7.	  Map	  showing	  the	  geographic	  distribution	  of	  HHV8	  ORF-­‐K1	  subtypes	  	  
	  
ORF-­‐K1	  SUBTYPES	  IN	  SUB-­‐SAHARAN	  AFRICA	  
Subtype	  A5	  and	  B	  predominate	  in	  KS	  patients	  in	  sub-­‐Saharan	  Africa	  (Table	  4).	  The	  majority	  
of	  published	  studies	  of	  ORF-­‐K1	  sequence	  analysis	  in	  Africa	  are	  of	  small	  sample	  size.	  Zong	  
reported	  that	  among	  10	  endemic	  and	  AIDS-­‐KS	  samples	  from	  Africa,	  9	  were	  subtype	  B,	  and	  1	  
was	  subtype	  A5	  [Zong	  et	  al.,	  1999].	  Fouchard	  et	  al.,	  reported	  that	  among	  4	  samples	  of	  
African	  endemic	  and	  epidemic	  KS	  that	  were	  subtyped	  for	  ORF-­‐K1,	  3	  out	  of	  the	  4	  strains	  were	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A5,	  and	  1	  was	  B1	  [Fouchard	  et	  al.,	  2000].	  Among	  the	  32	  African	  strains	  from	  North,	  West	  
and	  Central	  Africa,	  reported	  by	  Lacoste	  et	  al.,	  the	  majority	  were	  either	  of	  the	  B	  subtype	  
(13/32)	  or	  the	  A5	  subtype	  (11/32),	  while	  the	  rest	  were	  subtype	  C.	  These	  African	  strains	  were	  
isolated	  from	  AIDS-­‐KS	  (19/32),	  endemic	  KS	  (5/32),	  multicentric	  Castleman	  disease	  (5/32),	  
classic	  KS	  (1/32)	  and	  transplant	  KS	  (2/32)	  [Lacoste	  et	  al.,	  2000].	  	  	  
	  
The	  largest	  analysis	  of	  ORF-­‐K1	  sequences	  in	  Africa	  to	  date	  is	  that	  of	  White	  et	  al.	  in	  
Zimbabwe.	  Among	  65	  Zimbabwean	  AIDS-­‐KS	  patients,	  26/65(40%)	  were	  ORF-­‐K1	  subtype	  A	  
and	  39/65	  (60%)	  were	  subtype	  B.	  Zimbabwean	  subtype	  A	  sequences	  grouped	  only	  with	  A5,	  
while	  subtype	  B	  grouped	  with	  multiple	  clades:	  26	  B1	  (26/39	  67%),	  four	  B3	  (4/39	  10%)	  and	  
nine	  B4	  (9/39	  39%)	  [White	  et	  al.,	  2008].	  A5	  and	  B	  also	  predominated	  in	  a	  Ugandan	  study.	  
Among	  32	  samples	  of	  HHV8	  DNA	  isolated	  from	  Ugandan	  KS	  patients,	  17	  grouped	  as	  A5,	  9	  as	  
B1,	  1	  as	  B2,	  2	  as	  B3,	  1	  as	  subtype	  F	  and	  2	  as	  subtype	  C	  [Kajumbula	  et	  al.,	  2006].	  These	  same	  
Ugandan	  samples	  of	  Kajumbula	  were	  referred	  to	  in	  a	  review	  by	  Hayward	  and	  Zong,	  wherein	  
data	  of	  the	  whole	  genome	  was	  presented.	  They	  did	  not	  regard	  the	  2	  B3	  cases	  as	  being	  
distinctly	  different	  from	  subtype	  B2,	  and	  	  included	  them	  as	  B2	  cases	  [Hayward	  and	  Zong,	  
2007].	  	  
	  
In	   South	   Africa	   with	   its	   high	   HIV/KS	   burden,	   there	   is	   a	   paucity	   of	   data	   regarding	   the	  
epidemiology	  and	  prevalence	  of	  HHV8	  ORF-­‐K1	  subtypes.	  In	  a	  small	  South	  African	  study	  of	  21	  
KS	  patients	   (14	  with	   iatrogenic	  KS,	  6	  with	  African	  endemic	  KS	  and	  1	  with	  primary	  effusion	  
lymphoma)	  conducted	  in	  2002,	  10	  patients	  (8	  black	  and	  2	  of	  mixed	  of	  ancestry)	  were	  ORF-­‐
K1	  subtyped.	  The	  ORF-­‐K1	  subtypes	  were	  A5	  (3/10),	  B2	  (6/10)	  and	  1	  novel	  B	  variant.	  These	  
results	   support	   those	   of	   other	   studies	   in	   sub-­‐Saharan	   Africa	   [Fouchard	   et	   al.,	   2000;	  
Kajumbula	  et	  al.,	  2006;	  Lacoste	  et	  al.,	  2000;	  Zong	  et	  al.,	  1999].	  Four	  of	  these	  10	  patients	  had	  
iatrogenic	  KS	   (3	  B2,	  1	  A5),	   5	  patients	  were	  African	  endemic	  KS	   (2	  B2,	  2	  A5	  and	  1	  novel	  B	  
variant)	  and	  1	  had	  AIDS	  PEL	  (B2)	  [Treurnicht	  et	  al.,	  2002].	  Hayward	  and	  Zong	  reported	  on	  15	  
South	   African	   HHV8	   KS	   samples	   (KS	   type	   not	   specified),	   which	   did	   not	   include	   those	   of	  
Treurnicht.	  The	  whole	  genomic	  structure	  was	  evaluated	   in	  14	  of	   the	  samples.	  The	  ORF-­‐K1	  
subtypes	  were	  A5	  (7/15),	  B2	  (3/15),	  B1	  (3/15)	  and	  A4	  (2/15)	  [Hayward	  and	  Zong,	  2007].	  
	  
Table	  4.	  Summary	  of	  studies	  of	  ORF-­‐K1	  subtyping	  in	  sub-­‐Saharan	  Africa	  
   26  
Study	   N	   Origin	   *KS	  type	  and	  
prevalence	  
HHV8	  subtype	  and	  
prevalence	  
Zong	  et	  al.,	  
1999	  




1	  African	  endemic	  
9	  AIDS-­‐KS	  
9	  B	  (1	  African	  endemic,	  8	  
AIDS-­‐KS)	  
1	  A5	  (AIDS-­‐KS)	  
Fouchard	  
et	  al.,	  2000	  
4	   Central	  African	  Republic	  
Cameroon	  
French	  Guyana	  
1	  African	  endemic	  
3	  AIDS-­‐KS	  
1	  B1	  (AIDS-­‐KS)	  




32	   North,	  West	  and	  Central	  
Africa	  
19	  AIDS-­‐KS	  




14	  B	  (8	  AIDS-­‐KS,	  2	  African	  
endemic,	  1	  classic,	  3	  
Castleman)	  
11	  A5	  (8	  AIDS-­‐KS,	  1	  
African	  endemic,	  2	  
iatrogenic)	  
2	  A	  (1	  AIDS-­‐KS,	  1	  
Castleman)	  




1	  novel	  subtype	  (AIDS-­‐KS)	  
Treurnicht	  
et	  al.,	  2002	  
10	   South	  Africa	   4	  iatrogenic	  KS	  
5	  African	  endemic	  	  
1	  PEL	  
3	  A5	  (1	  iatrogenic,	  2	  
African	  endemic)	  
6	  B2	  (3	  iatrogenic,	  2	  
African	  endemic,	  1	  
PEL)	  
1	  novel	  B	  (African	  
endemic)	  
Kajumbula	  
et	  al.,	  2006	  






















(includes	  those	  of	  
Kajumbula	  et	  al.,	  2006)	  




KS	  (not	  specified)	  


























	  	  PBMC	  
AIDS-­‐KS	  
3	  F	  (AIDS-­‐KS)	  
	  
2	  F	  (AIDS-­‐KS)	  














	  	  2	  PBMC	  
2	  no	  KS	  (HIV+)	  
	  	  PBMC	  
3	  AIDS-­‐KS	  
	  	  PBMC	  
6	  no	  KS	  (4	  HIV+;	  2	  
HIV-­‐)	  
	  	  PBMC	  
1	  A1	  (AIDS-­‐KS)	  
1	  A5	  (no	  KS)	  
4	  B	  (3	  AIDS-­‐KS,	  1	  no	  KS)	  	  
9	  B	  (3	  AIDS-­‐KS,	  6	  no	  KS)	  
Tornesello	  

















African	  endemic	  	  
AIDS-­‐KS	  
5	  A5	  (African	  endemic)	  
2	  B1	  (African	  endemic)	  
4	  B3	  (African	  endemic)	  
1	  C	  (African	  endemic)	  
3	  A5	  (African	  endemic)	  
3	  A5	  (AIDS-­‐KS)	  
1	  B1	  (AIDS-­‐KS)	  
1	  C	  (AIDS-­‐KS)	  
1	  F	  (AIDS-­‐KS)	  
Kakoola	  et	  
al.,	  2001	  
17	   Uganda	   KS	  (not	  specified)	   5	  A5	  	  
11	  B	  (not	  specified)	  
1	  C	  
Olp	  et	  al.,	  
2015	  
16	   Uganda	   12	  AIDS-­‐KS	  
4	  African	  endemic	  
1	  A5	  (AIDS-­‐KS)	  
8	  B1	  (6	  AIDS-­‐KS;	  2	  African	  
endemic)	  
2	  B3	  (AIDS-­‐KS)	  
5	  B4	  (3	  AIDS-­‐KS;	  2	  African	  
endemic)	  
Olp	  et	  al.,	  
2013	  
31	   Zambia	   No	  KS	  (9	  HIV	  +;	  15	  
HIV-­‐;	  7	  HIV	  status	  
unknown)	  
	  	  Buccal	  swabs	  
17	  A5	  (8	  HIV+;	  7HIV-­‐)	  
14	  B	  (1	  HIV+;	  8	  HIV-­‐)	  
*All	  KS	  typing	  done	  on	  biopsy	  tissue	  from	  KS	  lesions	  unless	  otherwise	  specified	  
PBMC=	  peripheral	  blood	  monocyte	  count	  
	  
PROPOSED	  HYPOTHESIS	  FOR	  GEOGRAPHIC	  DISTRIBUTION	  OF	  HHV8	  SUBTYPES	  
Zong	  and	  Hayward	  proposed	  that	  HHV8	  is	  a	  relatively	  old	  human	  virus	  that	  evolutionarily	  
radiated	  along	  with	  early	  human	  populations	  migrating	  out	  of	  Africa,	  resulting	  in	  HHV8	  
genotypes	  that	  are	  distributed	  along	  broad	  geographic	  and	  ethnic	  lines	  [Hayward,	  1999;	  
Zong	  et	  al.,	  1999].	  HHV8	  like	  all	  herpes	  viruses	  is	  an	  old	  human	  virus	  that	  has	  co-­‐evolved	  and	  
adapted	  with	  the	  human	  host.	  According	  to	  the	  theories	  of	  Zong	  and	  Hayward,	  HHV8	  
subtypes	  evolved	  as	  modern	  humans	  migrated	  out	  of	  Africa	  in	  3	  waves:	  the	  first	  100,000	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years	  ago	  that	  failed	  to	  reach	  beyond	  the	  Middle	  East;	  the	  second	  60,000	  years	  ago	  which	  
reached	  South	  Asia	  and	  Australia,	  and	  the	  third	  wave	  to	  Northern	  Asia	  and	  Southern	  
Europe,	  35,000	  years	  ago.	  Expansions	  into	  the	  Americas,	  the	  Northern	  parts	  of	  Europe	  and	  
the	  Pacific	  islands	  occurred	  15,000	  years,	  10,000	  years,	  and	  4,000	  years	  ago	  respectively	  
(Figure	  8).	  Cook	  and	  Zong	  proposed	  that	  subtype	  B	  is	  the	  more	  ancient	  strain,	  originating	  in	  
Africa,	  and	  that	  A	  and	  C	  correspond	  to	  European	  and	  Northern	  American	  HHV8	  genotypes	  
[Cook	  et	  al.,	  1999;	  Zong	  et	  al.,	  1999].	  Hayward	  proposed	  that	  subtype	  B	  arose	  100,000	  years	  
ago	  as	  humans	  spread	  throughout	  Africa,	  subtype	  D	  was	  generated	  by	  a	  founder	  effect	  
within	  small	  populations	  of	  the	  first	  human	  migration	  into	  South	  Asia	  60,000	  years	  ago;	  and	  
subtype	  A	  and	  C	  arose	  35,000	  years	  ago	  as	  modern	  humans	  entered	  Europe	  and	  North	  Asia,	  
based	  on	  evidence	  of	  human	  migrations	  and	  the	  length	  of	  the	  branches	  in	  the	  ORF-­‐K1	  
phylogenetic	  trees	  [Hayward,	  1999;	  Zong	  et	  al.,	  1999].	  Within	  A	  and	  C	  subtypes,	  individual	  
clades	  arose	  between	  10,000	  and	  12,000	  years	  ago.	  The	  original	  divergence	  of	  the	  B	  subtype	  
into	  B1	  and	  B2	  clades	  appears	  to	  have	  occurred	  between	  25	  000	  and	  30	  000	  years	  ago	  
[Hayward	  and	  Zong,	  2007].	  
	  
	  
Studies	  have	  reported	  that	  A5	  is	  widespread	  throughout	  Africa,	  and	  also	  suggests	  an	  African	  
origin	  for	  this	  genotype	  [Lacoste	  et	  al.,	  2000].	  According	  to	  Hayward	  et	  al.,	  A5	  may	  have	  
been	  introduced	  by	  a	  single	  source	  from	  Europe	  or	  North	  Africa	  into	  a	  B	  subtype	  genome	  in	  
ancestors	  of	  the	  Bantu	  people,	  which	  spread	  through	  sub-­‐Saharan	  Africa	  with	  the	  Bantu	  
expansion	  from	  West	  Africa	  about	  4,000	  years	  ago.	  The	  term	  Bantu	  people	  is	  used	  to	  denote	  
ethnic	  groups	  in	  Africa	  who	  speak	  Bantu	  languages	  and	  inhabit	  a	  geographical	  area	  
extending	  from	  central	  to	  southern	  Africa.	  The	  Bantu	  expansion	  into	  South	  Africa	  reached	  
KwaZulu-­‐Natal	  by	  300A.D.	  and	  the	  Northern	  Province	  by	  500A.D,	  and	  may	  account	  for	  the	  
presence	  of	  A5	  in	  South	  Africa.	  The	  hypothesis	  of	  Hayward	  et	  al.	  to	  explain	  the	  distribution	  
of	  A5	  in	  Africa	  is	  that	  A5	  evolved	  in	  Africa	  through	  a	  rapid	  and	  recent	  aggressive	  spread	  
through	  recombinant	  events,	  which	  was	  augmented	  by	  the	  strong	  selective	  advantage	  
offered	  by	  the	  A5	  allele.	  In	  support	  of	  this	  theory,	  all	  subtype	  A5	  typed	  to	  date	  are	  
recombinant	  chimeras	  in	  which	  a	  very	  small	  portion	  of	  the	  left	  hand	  side	  of	  the	  genome	  
(ORF-­‐K1)	  is	  A-­‐like,	  hence	  classified	  as	  subtype	  A5,	  while	  the	  remainder	  is	  made	  up	  of	  the	  
African-­‐specific	  B,	  Q,	  R	  and	  N	  subtype	  constant	  region	  genomes,	  which	  as	  mentioned	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previously,	  are	  found	  exclusively	  in	  sub-­‐Saharan	  Africa	  [Hayward	  and	  Zong,	  2007].	  Many	  
South	  African	  genomes	  with	  ancient	  N	  type	  segments	  of	  presumed	  Khoisan	  or	  mixed	  
Bantu/Khoisan	  origin,	  are	  ORF-­‐K1	  subtype	  A5,	  suggesting	  that	  recombinant	  events	  occurred	  
once	  Bantu	  chimeric	  genomes	  interacted	  with	  Khoisan	  South	  African	  genomes	  [Hayward,	  
1999;	  Hayward	  and	  Zong,	  2007]..	  South	  Africa	  has	  a	  diverse	  population	  and	  factors	  such	  as	  
European	  and	  Asian	  colonization,	  human	  migration	  within	  Africa	  and	  the	  resultant	  mixed	  
ancestry	  will	  affect	  the	  prevalence	  of	  the	  subtypes	  in	  the	  South	  African	  population.	  	  
	  
	  
Figure	  8.	  The	  global	  ORF-­‐K1	  subtype	  distribution	  patterns	  correlate	  with	  the	  human	  
migration	  out	  of	  Africa	  over	  the	  past	  100,000	  years.	  Arrows	  indicate	  geographic	  direction	  
and	  timing	  of	  migration	  [Hayward,	  1999].	  	  
	  
	  
EVOLUTIONARY	  ADVANTAGE	  OF	  ORF-­‐K1	  	  
Variability	  within	  the	  ORF-­‐K1	  gene	  displays	  very	  high	  non-­‐synonymous	  rates,	  with	  up	  to	  85%	  
of	  nucleotide	  changes	  producing	  amino	  acid	  changes.	  (Nucleotide	  substitutions	  that	  do	  not	  
lead	  to	  amino	  acid	  substitutions	  are	  called	  synonymous	  substitutions;	  and	  those	  that	  do	  
   30  
lead	  to	  amino	  acid	  substitutions	  are	  called	  non-­‐synonymous	  substitutions.)	  This	  implies	  that	  
the	  changes	  are	  not	  random	  and	  that	  a	  powerful	  biological	  selection	  process	  is	  involved	  
[Hayward	  and	  Zong,	  2007].	  The	  advantage	  of	  the	  rapidity	  of	  evolution	  of	  ORF-­‐K1	  subtypes	  of	  
HHV8	  is	  yet	  to	  be	  elucidated,	  but	  may	  be	  due	  to	  a	  need	  of	  the	  virus	  to	  evade	  the	  immune	  
system	  and	  establish	  persistent	  infection	  as	  described	  in	  HHV6	  [Lusso	  et	  al.,	  1995].	  Zong	  
suggests	  however,	  that	  it	  is	  implausible	  that	  it	  is	  just	  a	  mechanism	  to	  evade	  recognition	  by	  
antibodies,	  as	  the	  herpes-­‐virus	  infected	  cells	  are	  more	  susceptible	  to	  cell-­‐mediated	  rather	  
than	  humoral	  immunity.	  He	  has	  proposed	  that	  the	  evolutionary	  advantage	  may	  be	  biological	  
selection	  for	  recognition	  of	  cell	  surface	  markers	  that	  may	  allow	  the	  entry	  and	  survival	  of	  
HHV8	  into	  genetically	  appropriate	  host	  cells	  [Zong	  et	  al.,	  1999].	  	  
	  
CLINICAL	  CORRELATION	  
Hayward	  first	  postulated	  that	  the	  ORF-­‐K1	  has	  a	  role	  in	  HHV8	  biology	  based	  on	  the	  following	  
facts.	  Firstly,	  ORF-­‐K1	  is	  the	  positional	  analogue	  of	  key	  latent	  transforming	  proteins	  in	  EBV	  
and	  HVS	  which	  affect	  T	  and	  B-­‐cell	  proliferation	  and	  tumorigenesis.	  Secondly,	  ORF-­‐K1	  
contains	  conserved	  protein	  tyrosine	  kinase	  interaction	  motifs	  which	  are	  very	  rare	  in	  viral	  
proteins.	  Thirdly,	  the	  observed	  genetic	  variability	  in	  ORF-­‐K1	  is	  not	  random,	  but	  appears	  to	  
be	  due	  to	  powerful	  positive	  biological	  selection	  process.	  Sixty	  two	  percent	  of	  the	  289	  amino	  
acids	  in	  ORF-­‐K1	  vary,	  and	  85%	  of	  the	  nucleotide	  changes	  result	  in	  amino	  acid	  changes	  
implying	  that	  the	  changes	  are	  not	  random,	  but	  due	  to	  positive	  selection.	  The	  level	  of	  
hypervariability	  in	  ORF-­‐K1	  is	  not	  seen	  in	  any	  other	  genes	  of	  HHV8	  [Hayward,	  1999].	  	  
	  	  
It	  has	  been	  proposed	  that	  different	  subtypes	  may	  have	  different	  pathogenic	  and	  
tumorigenic	  properties	  [Hayward,	  1999;	  Schwartz,	  1996].	  Conflicting	  data	  exists	  in	  the	  
literature.	  Some	  studies	  have	  shown	  subtype	  A	  to	  be	  linked/associated	  with	  more	  rapidly	  
progressing	  disease,	  more	  advanced	  disease	  and	  frequent	  mucosal	  and/or	  visceral	  KS	  
[Boralevi	  et	  al.,	  1998;	  Mancuso	  et	  al.,	  2008;	  Zhang	  et	  al.,	  2008]	  (Table	  5).	  
	  
In	  an	  Italian	  study,	  subtype	  A	  has	  been	  linked	  with	  more	  rapidly	  progressing	  disease	  in	  
classic	  KS	  [Mancuso	  et	  al.,	  2008].They	  classified	  patients	  with	  classic	  KS	  in	  to	  two	  groups	  
based	  on	  the	  clinical	  evolution	  of	  the	  disease:	  of	  the	  24/38	  that	  were	  ORF-­‐K1	  subtyped,	  
17/24	  were	  classified	  as	  fast	  progressors	  and	  7/24	  as	  slow	  progressors.	  HHV8	  subtype	  A	  was	  
   31  
present	  in	  rapid	  progressors	  12/17(71%)	  and	  in	  only	  1/7	  slow	  progressors,	  while	  subtype	  C	  
was	  mainly	  present	  in	  slow	  progressors	  (6/7cases).	  Subtype	  A	  also	  associated	  with	  
significantly	  higher	  blood	  HHV8	  viral	  loads	  (p=0,0054).	  The	  authors	  concluded	  that	  careful	  
monitoring	  and	  aggressive	  therapeutic	  protocols	  should	  be	  considered	  in	  patients	  with	  
subtype	  A	  [Mancuso	  et	  al.,	  2008].	  This	  observation	  confirmed	  previous	  findings	  of	  Boralevi	  
et	  al.,	  who	  reported	  that	  HHV8	  subtype	  A	  was	  associated	  with	  more	  advanced	  disease,	  
frequent	  mucosal	  and/or	  visceral	  KS	  (63%	  in	  A	  vs.	  27%	  in	  B,	  p<0,05)	  amongst	  HHV8	  isolates	  
from	  40	  white	  French	  AIDS-­‐KS	  cases	  evaluated.	  They	  concluded	  that	  subtype	  A	  displayed	  
more	  aggressive	  pathogenicity	  [Boralevi	  et	  al.,	  1998].	  Zhang	  et	  al.,	  in	  Xinjang,	  China,	  showed	  
that	  HHV8	  subtype	  A	  was	  associated	  with	  more	  frequent	  mucosal	  lesions	  than	  subtype	  C	  
[Zhang	  et	  al.,	  2008].	  Of	  27	  patients	  included	  in	  their	  study	  (23	  classic	  KS,	  4	  AIDS-­‐KS),	  ORF-­‐K1	  
could	  be	  amplified	  in	  22.	  Subtype	  A	  was	  associated	  with	  significantly	  more	  frequent	  mucosal	  
involvement	  (75%	  in	  subtype	  A	  vs	  11%	  in	  subtype	  C;	  p=	  0,024).	  Following	  Hayward’s	  
hypothesis	  that	  different	  subtypes	  may	  have	  different	  pathogenic	  properties,	  other	  studies	  
addressing	  HHV8	  epidemiology	  have	  looked	  for	  an	  association	  between	  subtype	  and	  clinical	  
presentation;	  however	  no	  association	  was	  found	  [Cook	  et	  al.,	  1999;	  Lacoste	  et	  al.,	  2000;	  
Meng	  et	  al.,	  1999;	  White	  et	  al.,	  2008;	  Zong	  et	  al.,	  1999].	  Reasons	  for	  this,	  could	  include	  the	  
diversity	  of	  populations	  studied,	  the	  heterogeneity	  amongst	  studies	  including	  methods	  
used,	  different	  clinical	  parameters	  assessed,	  and	  population	  size.	  
	  
Table	  5.	  Studies	  showing	  a	  correlation	  of	  HHV8	  subtypes	  with	  clinical	  presentation	  




24	  Italian	  classic	  KS	   Subtype	  A	  present	  in	  rapid	  
progressors	  (12/17)	  
Subtype	  C	  present	  in	  slow	  
progressors	  (6/7)	  
Subtype	  A	  higher	  blood	  viral	  
loads	  (p=0,005)	  
More	  careful	  monitoring	  





40	  French	  AIDS-­‐KS	   Subtype	  A	  more	  advanced,	  
mucosal	  and/or	  visceral	  
disease	  (p<0,05)	  




27	  Chinese	  (23	  
classic	  KS,	  4	  AIDS-­‐
KS)	  
Subtype	  A	  more	  mucosal	  
involvement	  than	  
subtype	  C	  (p=0,024)	  
Further	  study	  is	  needed	  to	  
establish	  whether	  HHV8	  
subtyping	  is	  correlated	  
with	  KS	  clinical	  
presentation	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An	  association	  between	  subtypes	  and	  clinico-­‐epidemiological	  forms	  of	  KS	  has	  been	  reported	  
in	  some	  studies	  [Gazouli	  et	  al.,	  2004;	  Ramos	  da	  Silva	  et	  al.,	  2011]	  (Table	  6),	  but	  not	  in	  others	  
[Cook	  et	  al.,	  1999;	  Lacoste	  et	  al.,	  2000;	  Meng	  et	  al.,	  1999;	  White	  et	  al.,	  2008;	  Zong	  et	  al.,	  
1999].	  Gazouli	  reported	  a	  study	  of	  HHV8	  typing	  in	  15	  iatrogenic	  KS,	  5	  AIDS-­‐KS,	  11	  classic	  KS,	  
and	  60	  healthy	  individuals	  from	  Greece.	  HHV8	  ORF-­‐K1	  sequences	  were	  isolated	  in	  30/31	  KS	  
and	  10/60	  healthy	  individuals.	  C3	  was	  found	  in	  17	  cases;	  12/17	  were	  iatrogenic	  KS,	  and	  5/17	  
healthy	  individuals.	  C1	  was	  found	  in	  3	  cases;	  2/3	  were	  iatrogenic	  and	  1/3	  classic	  KS.	  A4	  was	  
found	  only	  in	  the	  AIDS-­‐KS	  cases	  (5/5).	  A1	  was	  found	  in	  12	  cases;	  10/12	  were	  classic	  KS	  and	  2	  
healthy	  individuals.	  Gazouli	  thus	  suggested	  a	  possible	  involvement	  of	  subtype	  C3	  in	  renal	  
transplant	  KS,	  A4	  in	  AIDS-­‐KS	  and	  A1	  in	  classic	  KS	  in	  Greece	  [Gazouli	  et	  al.,	  2004].	  Distribution	  
of	  ORF-­‐K1	  variants	  amongst	  classic	  and	  AIDS-­‐KS	  in	  the	  United	  States	  showed	  predominantly	  
C	  subtypes	  in	  classic	  KS	  (6/10)	  while	  AIDS-­‐KS	  were	  predominantly	  subtype	  A	  (17/24;	  vs	  6/24	  
subtype	  C),	  but	  this	  was	  not	  statistically	  evaluated	  [Zong,	  2002].	  More	  recently,	  da	  Silva	  et	  
al.	  reported	  that	  out	  of	  50	  KS	  cases	  (22	  AIDS-­‐KS,	  14	  HIV-­‐negative	  KS,	  14	  KS	  not	  otherwise	  
specified)	  evaluated	  in	  Brazil,	  an	  elevated	  frequency	  of	  HHV8	  subtype	  A	  was	  found	  in	  HIV-­‐
positive	  patients	  (15/22;	  68%).	  Conversely,	  the	  majority	  of	  KS	  isolated	  from	  HIV-­‐negative	  
patients	  had	  subtype	  C	  (10/14;	  71%).	  The	  difference	  in	  proportions	  between	  A	  and	  C	  
subtypes	  within	  HIV-­‐positive	  and	  HIV-­‐negative	  patients	  was	  statistically	  significant	  (p=0,026,	  
Fisher’s	  exact	  test)	  [Ramos	  da	  Silva	  et	  al.,	  2011].	  This	  data	  raises	  the	  question	  as	  to	  whether	  
subtype	  A	  has	  unique	  biological	  features	  and	  suggests	  a	  possible	  HIV/HHV8	  interaction.	  	  
	  
Table	  6.	  Studies	  showing	  a	  correlation	  between	  HHV8	  subtypes	  and	  clinico-­‐epidemiological	  
forms	  of	  KS	  
Study	   Sample	  size	   Result	   Conclusion	  
Gazouli	  et	  al.,	  2004	  
Greece	  
15	  iatrogenic	  KS	  
5	  AIDS-­‐KS	  
11	  classic	  KS	  
60	  healthy	  
individuals	  
Subtype	  A4	  in	  5/5	  
AIDS-­‐KS;	  
Subtype	  C	  in	  2/3	  
iatrogenic	  KS	  
Subtype	  C	  in	  1/3	  
classic	  KS;	  
A1	  in	  10/12	  classic	  KS	  	  
Suggested	  a	  possible	  
involvement	  of	  
subtype	  C	  in	  
iatrogenic	  KS;	  A4	  in	  
AIDS-­‐KS;	  A1	  in	  
classic	  KS	  in	  Greece	  




14	  HIV	  negative	  
14	  KS	  not	  
Subtype	  A	  found	  in	  
15/22	  HIV-­‐positive	  
Subtype	  C	  in	  10/14	  
Distinct	  subtypes	  
have	  a	  non-­‐random	  
distribution,	  possibly	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specified)	   HIV-­‐negative	  
(p=0,026)	  
due	  to	  unique	  
biological	  properties	  
	  
Only	  one	  study	  has	  found	  an	  association	  between	  subtype	  B	  and	  biological	  properties.	  Kouri	  
et	  al.,	  in	  their	  study	  of	  HHV8	  in	  90	  KS	  samples	  in	  Cuba,	  reported	  an	  association	  with	  subtype	  
B	  and	  heterosexual	  behaviour	  (OR	  3,63;	  CI	  1,2-­‐10,98,	  p=0,03),	  with	  having	  antecedently	  
acquired	  HIV/HHV8	  in	  Africa	  (p=0,0003)	  and	  with	  histologically	  nodular	  stage	  KS	  (OR	  4,2;	  CI	  
1,1-­‐15,7;	  p=0,04).	  They	  proposed	  that	  these	  findings	  may	  be	  related	  to	  a	  more	  rapid	  
evolution	  and/or	  virulence	  of	  HHV8	  subtype	  B	  [Kouri	  et	  al.,	  2012].	  The	  authors	  concluded	  
that	  this	  observation	  warrants	  further	  study	  as	  there	  are	  no	  consistent	  reports	  linking	  HHV8	  
subtypes	  with	  epidemiologic	  variants,	  clinical	  stage	  or	  with	  evolution	  of	  disease.	  	  
	  
Treurnicht’s	  study	  found	  no	  correlation	  between	  genetic	  subtype,	  geographical	  origin	  of	  the	  
patients	  or	  the	  KS	  clinical	  variants	  (iatrogenic	  or	  African	  endemic	  KS),	  but	  the	  numbers	  in	  
this	  study	  were	  very	  small	  [Treurnicht	  et	  al.,	  2002].	  
	  
IDENTIFICATION	  OF	  GAPS	  OR	  NEEDS	  FOR	  FURTHER	  RESEARCH	  
The	  majority	  of	  the	  published	  studies	  in	  Africa,	  reported	  on	  HHV8	  diversity	  in	  East	  [Cook	  et	  
al.,	  1999;	  Hayward,	  1999;	  Meng	  et	  al.,	  1999;	  Zong	  et	  al.,	  1999;	  Olp	  et	  al.,	  2015;	  Kakoola	  et	  
al.,	  2001;	  Tornesello	  et	  al.,	  2010],	  West	  and	  Central	  Africa	  [Cook	  et	  al.,	  1999;	  Fouchard	  et	  al.,	  
2000;	  Lacoste	  et	  al.,	  2000].	  There	  is	  a	  paucity	  of	  data	  on	  the	  prevalence	  and	  epidemiology	  of	  
the	  different	  HHV8	  subtypes	  in	  southern	  Africa.	  	  	  A	  limitation	  of	  the	  studies	  conducted	  in	  
Africa,	  are	  that	  they	  are	  all	  of	  small	  sample	  size,	  except	  for	  that	  of	  Kajumbula	  in	  Uganda	  (31	  
patients)	  and	  White	  in	  Zimbabwe	  (65	  patients)	  [Kajumbula	  et	  al.,	  2006;	  White	  et	  al.,	  2008].	  
In	  the	  South	  African	  study	  of	  Treurnicht,	  only	  10	  cases	  of	  KS	  were	  subtyped	  for	  ORF-­‐K1	  and	  
Hayward	  and	  Zong	  reported	  on	  15	  South	  African	  HHV8	  KS	  samples	  [Hayward	  and	  Zong,	  
2007;	  Treurnicht	  et	  al.,	  2002].	  There	  is	  a	  need	  for	  larger	  studies	  on	  epidemiology	  and	  
prevalence	  of	  HHV8	  subtypes	  in	  Africa,	  as	  well	  as	  South	  Africa	  which	  bear	  the	  brunt	  of	  the	  
HIV/HHV8	  KS	  burden.	  
	  
ORF-­‐K1	  displays	  the	  most	  nucleotide	  hypervariability	  within	  the	  genome	  leading	  to	  amino	  
acid	  changes,	  and	  hence	  may	  have	  functional	  significance.	  Despite	  the	  complexities	  of	  the	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HHV8	  genome	  including	  the	  new	  12	  subtypes	  proposed	  by	  Zong,	  and	  the	  limitation	  of	  only	  
subtyping	  one	  segment	  of	  the	  genome;	  there	  is	  considerable	  value	  obtained	  from	  subtyping	  
ORF-­‐K1	  for	  epidemiological	  reasons,	  as	  well	  as	  functional/	  clinico-­‐pathological	  reasons.	  	  
	  
The	  subtypes	  of	  HHV8	  are	  distributed	  along	  broad	  geographic	  and	  ethnic	  lines	  that	  have	  
been	  proposed	  to	  be	  a	  result	  of	  ancient	  human	  migrations	  and	  founder	  effects	  [Hayward,	  
1999;	  Zong	  et	  al.,	  1999].	  South	  Africa	  has	  a	  diverse	  population	  and	  factors	  such	  as	  European	  
and	  Asian	  colonization,	  human	  migration	  in	  Africa	  and	  resultant	  mixed	  ancestry	  should	  
affect	  the	  prevalence	  of	  the	  subtypes	  in	  the	  South	  African	  population.	  Hence	  it	  is	  of	  great	  
importance	  to	  study	  the	  epidemiology	  of	  the	  genetic	  subtypes	  of	  the	  South	  African	  
population.	  
	  
Although,	  conflicting	  data	  exists,	  numerous	  studies	  point	  to	  differing	  tumorigenic	  and	  
pathogenic	  properties	  of	  the	  HHV8	  subtypes,	  in	  particular	  to	  increased	  aggressivity	  of	  
subtype	  A	  [Boralevi	  et	  al.,	  1998;	  Mancuso	  et	  al.,	  2008;	  Zhang	  et	  al.,	  2008].	  Further	  research	  
is	  warranted	  to	  elucidate	  whether	  an	  association	  exists,	  which	  could	  affect	  disease	  
prognosis	  and	  direct	  future	  therapies.	  Other	  than	  the	  study	  of	  Treurnicht	  et	  al.	  and	  that	  of	  
Hayward	  and	  Zong,	  there	  are	  no	  recent	  South	  African	  studies	  in	  the	  literature	  examining	  the	  
prevalence	  of	  the	  different	  subtypes	  and	  how	  this	  correlates	  with	  clinical	  presentation	  of	  KS	  
[Hayward	  and	  Zong,	  2007;	  Treurnicht	  et	  al.,	  2002].	  
	  
A	  study	  was	  undertaken	  with	  the	  following	  objectives:	  
(1)	  to	  determine	  the	  prevalence	  of	  the	  HHV8	  ORF-­‐K1	  subtypes;	  and	  
(2)	  to	  analyse	  the	  associations	  between	  the	  different	  HHV8	  ORF-­‐K1	  subtypes,	  
different	  clinico-­‐epidemiologic	  forms,	  presentation,	  and	  stage	  of	  KS;	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Genetic Diversity of HHV8 Subtypes in South
Africa: A5 Subtype Is Associated With Extensive
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Human herpes virus 8 (HHV8) is the etiological
agent of all forms of Kaposi’s sarcoma (KS). Six
major subtypes (A-F), based on genetic variability
of open reading frame (ORF)-K1, have been
identified. Numerous studies point to differing
tumorigenic and pathogenic properties of the
HHV8 subtypes. The study objectives were to
determine the HHV8 subtypes and their preva-
lence in a cohort of clinical and histologically
confirmed KS in Cape Town, South Africa, and
analyze associations between the different sub-
types and clinical presentation of KS. Clinical
records were prospectively reviewed to extract
clinical presentation; demographic data were
retrospectively collected and tissue biopsies
were taken for ORF-K1 subtyping. Eighty six
patients were subtyped; 81 AIDS (acquired
immune deficiency syndrome)-KS and 5 African
endemic-KS. Subtype A5 (42/86) and B2 (16/86)
predominated. B1, B3, A1 and A4 subtypes were
identified in 10/86, 9/86, 4/86 and 1/86 patients,
respectively. A5 and B subtypes were found in
African blacks and individuals of mixed ancestry,
while subtypes A1 and A4 were found only in
whites and individuals of mixed ancestry. Sub-
type A5 was associated with >10 KS lesions at
presentation in the AIDS cohort (adjusted OR:
3.13; CI: 1.02–9.58). Subtypes A1 and A4 com-
bined were less likely to be associated with poor
risk tumor extension (P¼ 0.031) and A1 was
associated with lower likelihood of lower limb
involvement (P¼ 0.019). In conclusion, these re-
sults indicate that subtype A5 and B predominate
in South Africa and A5 may be associated with
more extensive disease. J. Med. Virol. 88:292–
303, 2016. # 2015 Wiley Periodicals, Inc.
KEY WORDS: Kaposi’s sarcoma; human
herpes virus 8; HHV8; KSHV;
ORF-K1
INTRODUCTION
Kaposi’s sarcoma (KS) is a multifocal proliferative
disorder involving blood and lymphatic vessels. The
etiological agent of KS was elucidated in 1994 and is a
KS-associated herpes virus (KSHV) also known as
human herpes virus 8 (HHV8) (family Herpesviridae,
subfamily Gammaherpesvirinae, genus Rhadinovirus)
[Chang et al., 1994]. This virus is also associated with
the development of B-cell primary effusion lymphoma
(PEL) and multicentric Castleman’s disease [Ablashi
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et al., 2002]. KS is an AIDS-defining disease; it is the
most common AIDS-related malignancy worldwide and
is one of the most common cancers in sub-Saharan
Africa [Wabinga et al., 1993; Morris, 2003].
There are four principal clinical variants of KS,
namely, classic KS, African endemic KS, iatrogenic
KS, and AIDS-related KS. The HIV pandemic has
seen the incidence of Kaposi’s sarcoma (KS) in sub-
Saharan Africa rise by between three- and twenty-
fold [Parkin et al., 1999]. In South Africa over a
period of 23 years (1983–2006), age standardized
incidence rates increased 20-fold in men and 50-fold
in women [Mosam et al., 2009]. Adult seroprevalence
rates of HHV8 in South Africa amongst medical
patients and patients with sexually transmitted
diseases in KwaZulu Natal increase with age, rang-
ing from 32% in age group 15–34 to 63% among
adults aged 35–69 years [Wilkinson et al., 1999].
HHV8 is found in KS lesions of all types. Its genome
contains several genes that were pirated from
the human host and play an important role in the
pathogenicity of the virus. The HHV8 genome is mostly
highly conserved but both ends of the genome show
significant variability, which has been used as the basis
for viral genetic subtyping. Six major subtypes (A, B, C,
D, E, and F) and at least 13 different variants or clades
based on genetic variability of ORF-K1 gene sequences,
have been identified [Zong et al., 2002]. The different
subtypes have been shown to have variable penetrance
in various population groups and are distributed along
broad geographic and ethnic lines, which may have
arisen through ancient human migrations [Hayward,
1999; Zong et al., 1999; Zong et al., 2002]. Subtypes B
and A5 have been found to predominate in sub-Saharan
Africa [Cook et al., 1999; Hayward, 1999; Meng et al.,
1999; Zong et al., 1999; Fouchard et al., 2000; Lacoste
et al., 2000; Kajumbula et al., 2006]. A and C subtypes
are found in Caucasian patients throughout Europe, the
United States, the Mediterranean basin, the Middle
East and Asia [Cook et al., 1999; Zong et al., 1999] and
D in the Pacific islands and Taiwan [Zong et al., 1999;
Zhang et al., 2008]. In Brazil, there is a 53% prevalence
of subtype E in Brazilian Indians, but the study was
done on individuals without KS and, therefore, any
association between subtype E and KS development
remains to be studied [Biggar et al., 2000]. In addition,
recently, subtype F has been identified in Ugandans
with KS [Kajumbula et al., 2006].
It has been proposed that different genotypes may
have different pathogenic and tumorigenic properties
[Schwartz, 1996; Hayward, 1999]. Conflicting data
exist in the literature. While some studies have shown
subtype A to be associated with more rapidly progress-
ing disease, more advanced disease, frequent mucosal,
and/or visceral KS [Schwartz, 1996; Mancuso et al.,
2008; Zhang et al., 2008], other studies have failed to
confirm this [Cook et al., 1999; Meng et al., 1999; Zong
et al., 1999; Lacoste et al., 2000; White et al., 2008].
An association between subtypes and clinico-
epidemiological forms of KS has also been reported in
some studies [Gazouli et al., 2004; Ramos da Silva
et al., 2011], but not in others [Cook et al., 1999;
Meng et al., 1999; Zong et al., 1999; Lacoste et al.,
2000; White et al., 2008]. An elevated frequency of
HHV8 subtype A as opposed to subtype C has been
reported in AIDS-KS in Brazil [Ramos da Silva et al.,
2011]. Gazouli also suggested a possible involvement
of subtype A4 in AIDS-KS, subtype A1 in classic KS,
and subtype C3 in renal transplant KS in Greece
[Gazouli et al., 2004]. These data raise the question
as to whether subtype A has unique biological
features. Conversely, a Cuban study of 90 KS cases,
the first to report HHV8 subtype B expansion
in Cuba, found an association between subtype B
with heterosexual behavior (OR: 3.63, CI: 1.2–10,98;
P¼ 0.03) and having acquired HHV8 in Africa
(P¼ 0.0003) [Kouri et al., 2012].
There are limited data on the prevalence or epidemi-
ology of the different HHV8 subtypes in South Africa.
In a small South African study of 21 KS patients
(14 iatrogenic KS, 6 African endemic KS, and 1 AIDS
PEL) conducted in 2002, no correlation was reported
between genetic subtype, geographical origin of pa-
tients or clinical variants [Treurnicht et al., 2002].
This lack of association may be due to the small
number of patients studied and subtyped, since only 10
patients (4 iatrogenic, 5 African endemic and 1 AIDS
PEL), were subtyped for ORF-K1 variants. Subtype B2
was identified in six patients (two African endemic KS,
three iatrogenic KS 3, one AIDS PEL) and A5 in three
patients (two African endemic KS, one iatrogenic KS).
A novel B variant was found in one case of African
endemic KS [Treurnicht et al., 2002]. In addition,
Hayward and Zong reported on ORFK-1 subtyping in
15 South African HHV8 samples. The whole genomic
structure was evaluated in 14 of the samples. The
ORF-K1 subtypes were A5 (7/15), B2 (3/15), B1 (3/15),
and A4 (2/15), respectively [Hayward and Zong, 2007].
Although conflicting data exist, numerous studies
point to differing tumorigenic and pathogenic prop-
erties of the HHV8 subtypes. The prevalence of
these subtypes seems to be population specific. On
the basis of this information, a study of the preva-
lence of the HHV8 subtypes in a South African
population, with its high KS/HIV burden was under-
taken, with the aim of analyzing associations of the
different HHV8 subtypes, with clinico-epidemiologic
forms, presentation, and the stage of KS. These
associations may impact disease prognosis and direct
future therapies.
MATERIALS AND METHODS
Study Setting and Participants
The study population comprised patients present-
ing with an initial diagnosis of KS at Groote Schuur
Hospital, a tertiary referral center in Cape Town,
between January 1, 2009 and December 31, 2012.
Tissue samples consisted of 4mm punch biopsies of
KS skin lesions taken after obtaining informed
J. Med. Virol. DOI 10.1002/jmv
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consent. The biopsies were coded with a labeling
system that did not disclose the identity of the
patients and frozen at !20˚C. Skin lesions were
photographed prior to biopsy as part of standard of
care and the type and site of the lesions was recorded
on body charts.
Ethics Statement
Ethics approval for this study was obtained from
the University of Cape Town Human Research Ethics
Committee (HREC/REF: 279/2008) and complies with
the ethical standards of the Declaration of Helsinki.
Written informed consent was obtained from each
individual before sample collection.
Data Extraction
Patients with a clinical and histological diagnosis of
KS were included in the study. Clinical records of the
patients were retrospectively reviewed and the follow-
ing data parameters were extracted as follows: age, sex,
nationality, ethnicity (based on language as proxy), HIV
status, CD4 count, whether on antiretroviral therapy
(ART), chemotherapy, and presence of TB. Ethnicity
was grouped as black, white, and mixed race. Mixed
race in the South African context was defined as
historically a mixture black and white with contribu-
tions from Malay and other smaller ethnic groups.
Prospectively collected information on clinical presen-
tation, including the morphology of lesions and their
extent and distribution based on recorded body dia-
grams and photographs were analyzed. Lesion morphol-
ogy was classified as “patch,” “plaque,” “nodule,” or
“fungating” based on if explicitly described as such in
the medical record or labeled on the body diagram, or
identified from the photographs. Anatomic sites were
categorized as face, oral mucosa, trunk, upper limbs,
lower limbs, and genitalia. Cutaneous disease was
categorized as localized or generalized, based on defini-
tions utilized in previous literature [Nasti et al., 2003a;
Mosam et al., 2008]. KS lesions confined to one
anatomical area were classified as localized whether
unilateral or bilateral and lesions as generalized if more
than one anatomic site was involved. Cutaneous disease
extent was categorized as <10 or >10, with <10 lesions
indicating indolent disease [Nasti et al., 2003a].
Patients with AIDS-KS were retrospectively staged
according to the modified AIDS Clinical Trials Group
(ACTG) criteria proposed by Nasti in the era of
highly active antiretroviral therapy (HAART). This
was a refinement of the validated original ACTG
criteria, which was developed as a prognostic indica-
tor for the evaluation of AIDS-KS in the pre-HAART
era [Krown et al., 1989, 1997; Nasti et al., 2003a].
This modified ACTG criteria classifies patients into
risk categories for death depending on tumor extent
(T1 if tumor-associated edema or ulceration, nodular
oral KS, visceral KS; otherwise staged as T0) and
concomitant systemic illness (S1 if opportunistic
infections and/ or thrush, B symptoms present,
performance status <70%, other HIV related illness;
otherwise staged as S0). According to the modified
staging system, the combination of poor tumor stage
(T1) and poor systemic disease (S1) risk, identified
patients with unfavourable prognosis especially if
concomitant pulmonary involvement by KS was
present [Nasti et al., 2003b]. Due to insufficient
information available in the clinical records to allow
accurate staging for concomitant systemic illness,
patients were only staged by tumor extent (T1/T0).
PCR and Phylogenetic Analysis
Viral DNA was extracted from the biopsies using a
QIAamp DNA Kit (QIAGEN) according to the manu-
facturer’s recommendations. The full length of the
ORF-K1 gene was amplified using the following
primers, forward (50-GTTCTGCCAGGCATAGTC-30)
and reverse (50-AATAAGTATCCGACCTCAT-30) in a
reaction mix containing 1U of Taq DNA polymerase
(New England Biolabs, Ipswich, USA), 2.5mM
MgCl2, 200mM each dNTPs (New England Biolabs),
and 2ml of viral DNA in 20ml final volume. PCR
reaction was performed at 94˚C for 1min, 50˚C for
1min, and 72˚C for 2min over 35 cycles [Poole et al.,
1999]. The PCR product (1,065 bp) was then subjected
to direct nucleotide sequencing (Macrogen, Seoul,
South Korea) using the following primers: forward
(50-GGCCCTTGTGTAAACCTGTC-30) and reverse (50-
CCTGAATGTCAGTACCAATCCA-30) that span a re-
gion of 932 bp. Multiple sequence alignment of the
HHV8 ORF-K1 region from this study and reference
strains reported in the GeneBank were performed
using MEGA5 [Tamura et al., 2011]. The reference
sequences used are based on Zong et al. [1999],
Lacoste et al. [2000], Zhang et al. [2008], and
Tornesello et al. [2010]. Their accession numbers are
as follows: AF133038.1 (A1), FJ884626.1 (A1),
FJ884615.1 (A1), AF130305.1 (A1), AY204646.1 (A1),
AY204648.1 (A2), U86667.1 (A3), AF133039.1 (A4),
AF171057.1 (A5), AF178797.1 (A5), AY042955.1 (A5),
AF178798.1 (A5), AF178823.1 (A5), AF178801.1 (B1),
AF133040.1 (B1), AF178824.1 (B1), AF130259.1 (B2),
AY042940 (B3), AF133041.1 (C1), AF133042.1 (C3),
AF133043.1 (D1), AF133044.1 (D2), AF220292.1 (E),
and AF178810.1 (F). Subsequently, phylogenetic trees
were constructed by transforming the aligned
sequence data by the neighbor-joining bootstrap
values of 1,000 replicates using the maximum compo-
site likelihood (MCL) approach.
Statistical Analysis
Data were analyzed using STATA statistical package
(StataCorp, Version 13). Descriptive analysis using
medians with inter-quartile ranges (IQR) were used to
summarize age and CD4 count distributions.
Proportions are depicted as percentages for categorical
variables. A Pearson’s Chi-square (x2) or Fisher’s exact
test, depending on the size of the groups compared,
was used to test for strength of association between
J. Med. Virol. DOI 10.1002/jmv
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categorical variables. Data were tested for normality
and a Mann–Whitney test was used to test for strength
of association for continuous variables. A significance
level of P< 0.05 was used for all analysis.
Logistical regression was used to estimate the
independent association of HHV8 subtypes with
extent of KS in a multiple variable model.
RESULTS
Demographic Characteristics
Between January 1, 2009 and December 31, 2012,
103 adults were seen with a clinical and histological
diagnosis of KS. AIDS-KS was diagnosed in 96
patients (93%), African endemic KS in 5 patients
(5%), iatrogenic KS in 1 patient (1%), and classic KS
in 1 patient (1%) (Fig. 1). Eighty-six of the 103
patients were subtyped, and 17 were excluded since
subtyping was unsuccessful. Among the 86 patients
subtyped, AIDS-KS was diagnosed in 81 patients
(94%) and African endemic in 5 patients (6%). Fifty
three of the 86 subtyped patients (62%) were male.
The median age of the 86 patient cohort was 36 years
(IQR 31-42). The majority of the patients, 66/86
(77%), were South African. The remaining 20
patients (17 AIDS-KS and 3 African endemic KS)
were of African origin, other than South African.
There was no information available from their
clinical records as to their country of origin. The
ethnic distribution showed 74/86 (86%) black, 10/86
(12%) mixed race, and 2/86(2%) white (Table I).
Current co-infection with tuberculosis was
present in 31/86 (36%). Chemotherapy (vincristine
Fig. 1. Flow diagram showing the patients of the KS cohort and the determined HHV8
subtypes. U denotes an unclustered subtype.
TABLE I. General Characteristics of Patients and Genetic
Subtypes (n¼ 86)
Characteristic Value








Mixed race 10 (12)
KS type
AIDS-KS 81
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and bleomycin) for KS had been received by 11/86
(13%) patients. The median number of cycles of
chemotherapy received at the time seen was 1.5
(range 1–11 cycles).
Fifty six of the 81 AIDS-KS patient cohort (69%)
were on ART. The median CD4 count of the 81 AIDS-
KS patients was 153 cells/ml (IQR 83–288).
Sufficient clinical data were available to allow
ACTG T1 staging in 71/81 AIDS-KS patients. The KS
staging identified 58% (41/71) cases that were classi-
fied as poor risk tumor extension (T1).
Genetic Subtyping
Out of the 86 patients that were subtyped, 81
patients were diagnosed with AIDS-KS and 5 patients
were diagnosed with African endemic KS. The ORF-K1
gene of the 86 viral isolates was sequenced and the
accession numbers are indicated in Table II. A phylo-
genetic tree based on ORF-K1 coding region using
reference sequences was constructed (Fig. 2). Subtype
A5 was the most common (42/86; 49%), followed by B2
(16/86; 19%) and B1 (10/86; 12%) and B3 (9/86; 10%),
which are all subtypes prevalent in Africa. In addition,
four patients were infected with subtype A1 (5%) and
one patient with A4 (1%) which are viral subtypes that
have been shown to predominate in Europe and United
States (Tables I and II). Viral sequences of four
patients did not cluster with any of the classified
subtypes and were termed unclustered.
Clinical Presentation
Twenty one of 86 patients (24%) presented with
localized disease, and 65 patients (76%) with general-
ized disease (Table III).
Lesions involved the following locations on presenta-
tion: 45/86 (52%) face, 30/86 (35%) oral mucosa, 50/86
(58%) trunk, 45/86 (52%) upper limbs, 70/86 (81%)
lower limbs, and 6/86 (7%) genitalia. Lesions involving
two or more anatomic locations were seen in 65/86
(76%) of patients. At presentation, 62/86 (72%) pre-
sented with >10 lesions and 24/86 (28%) patients
displayed less than <10 lesions (Table III).
Twenty eight of the 86 (33%) patients presented
with patches, 72/86 (84%) presented with plaques,
32/86 (37%) presented with nodules, and 3/86 (4%)
presented with fungating lesions. Fifty two percent
(44/86) of patients presented with more than one KS
morphological type, while 42/86 (49%) presented with
one morphology. Dual morphology was seen in 39/86
(45%) and 5/86 (6%) presented with three morpholog-
ical types (Table III). Lymphoedema was associated
with KS lesions in 42/86 (49%) patients (Table III).
Clinical Correlations
Subtype A5 was strongly associated with >10
lesions at presentation in the AIDS-KS cohort. Thirty
two out of 38 AIDS-KS patients who had A5 subtype
had more than 10 lesions, while only 6 patients who
had A5 had less than 10 lesions (P¼ 0.050). This
correlation was not observed in the African endemic
KS group (P¼ 0.600) (Supplementary Table S1). The
strength of association of A5 with >10 lesions in
AIDS-KS is increased when only the known KS
subtypes are analyzed (P¼ 0.026). Multivariable anal-
ysis showed an independent association between
subtype A5 and >10 lesions (adjusted OR: 3.13; CI:
1.02–9.58), (Table IV).
Subtypes A1 and A4 occurred only in AIDS-KS.
Subtype A1 was less likely to be associated with
lower limb involvement, which was statistically sig-
nificant (P¼ 0.019). There was also a statistically
significant association between subtypes A1 and A4,
combined, and tumor stage. Subtypes A1 and A4
combined were less likely to be associated with poor
risk tumor extension (T1) (P¼ 0.031), and hence
associated with a better prognosis. Tumor stage T1
was associated with lower limb involvement
(P¼ 0.048). There was a strong association between
lower limb involvement and lymphoedema
(P¼ 0.008).
General Correlations
There was a strong association between ethnicity
and genetic subtype. Subtypes A1 (P< 0.001), A4
(P¼ 0.023) and A5 (P¼ 0.040) were associated with
ethnicity. B1, B2, and B3 individually showed a trend
toward an association with ethnicity, but this did not
reach statistical significance. Subtype A1 and A4
were found only in whites and patients of mixed
ancestry (P< 0.001 and P¼ 0.023, respectively). In
contrast, subtypes A5 (P¼ 0.040) and B (B1
P¼ 1.000; B2 P¼ 0.788; B3 P¼ 1.000) were not found
in white patients (Table V).
In the original cohort of 103, there was a statisti-
cally significant association between age and gender.
In the age group <35 years (42), 19/42(45%) were
male and 23/42(55%) were female, while in the age
group >35 years (60), 43/60 (72%) were male and
17/60 (28%) were female (P¼ 0.007).
DISCUSSION
This study adds to the current knowledge of the
worldwide epidemiology of HHV8 genetic subtypes,
by providing the largest sample of analysis of
ORF-K1 subtypes in South Africa and sub-Saharan
Africa. In this study, subtypes A5 and B were found
to be the predominant HHV8 subtypes. Subtype A5
was found to be associated with more extensive
lesions at presentation in AIDS-KS. Subtypes A1 and
A4 were not found amongst black patients. A1 was
associated with a lower likelihood of having lower
limb involvement. Within age group <35, there were
slightly more women than men with KS, while in the
age group >35 years, there were markedly more men
than women (P¼ 0.007).
Subtypes A5 and B predominate in South Africa.
This confirms results of previous studies that A5
J. Med. Virol. DOI 10.1002/jmv
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TABLE II. HHV8 Subtype According to Demographic Characteristics (n¼ 86)
KS no. Age Sex Race KS type ARV CD4 Stage HHV8 subtype
Accession
number
KS3 42 M BLACK AIDS-KS NO 1367 T0 A5 KP997035
KS4 39 M BLACK AIDS-KS NO 66 T0 B2 KP997036
KS5 45 F BLACK AIDS-KS YES 123 T1 B2 KP997037
KS6 25 M BLACK AIDS-KS NO UNKNOWN – B2 KP997038
KS8 30 M BLACK AIDS-KS NO 239 T1 B2 KP997039
KS9 46 F BLACK AIDS-KS NO 311 – A5 KP997040
KS11 21 F BLACK AIDS-KS NO 3 T0 U KP997041
KS14 37 M BLACK AIDS-KS NO 270 T1 B3 KP997043
KS17 35 F BLACK AIDS-KS NO 89 T1 A5 KP997044
KS19 38 M BLACK AIDS-KS NO 94 T0 B2 KP997045
KS20 31 M BLACK AIDS-KS YES 110 T0 A5 KP997046
KS22 40 M BLACK AIDS-KS NO 319 T1 B1 KP997047
KS25 48 F BLACK AFRICAN
ENDEMIC
N/A N/A T1 A5 KP997048
KS26 31 F BLACK AIDS-KS YES 99 T1 A5 KP997049
KS28 44 F BLACK AIDS-KS NO 289 T1 B2 KP997050
KS29 25 M BLACK AIDS-KS NO 160 T0 A5 KP997051
KS31 50 M BLACK AIDS-KS NO 74 T1 A5 KP997052
KS33 42 M WHITE AIDS-KS YES 150 T0 A1 KP997054
KS34 39 F BLACK AIDS-KS NO 219 T0 B2 KP997055
KS35 26 M BLACK AIDS-KS YES 91 T1 B2 KP997056
KS36 77 M BLACK AFRICAN
ENDEMIC
N/A N/A N/A A5 KP997057
KS37 41 F BLACK AIDS-KS YES 25 – A5 KP997058
KS38 36 M BLACK AIDS-KS YES 225 T1 A5 KP997059
KS39 37 M BLACK AIDS-KS YES UNKNOWN T0 B1 KP997060
KS40 62 M MIXED
RACE
AIDS-KS NO 322 T0 A1 KP997061
KS41 36 F BLACK AIDS-KS YES 699 T1 B2 KP997062
KS42 34 F BLACK AIDS-KS YES 65 T1 A5 KP997063
KS44 33 M BLACK AIDS-KS YES 132 T1 A5 KP997065
KS45 40 M MIXED
RACE
AIDS-KS YES 89 T1 B2 KP997066
KS46 33 F BLACK AIDS-KS NO 330 – B3 KP997067
KS48 30 M BLACK AIDS-KS NO 333 T1 B1 KP997069
KS49 38 F BLACK AIDS-KS YES 178 T1 A5 KP997070
KS50 24 F BLACK AIDS-KS YES 548 T1 B3 KP997071
KS51 . . BLACK AIDS-KS YES UNKNOWN T0 B1 KP997072
KS53 31 M BLACK AIDS-KS YES 173 T1 B1 KP997074
KS54 49 M BLACK AIDS-KS YES 92 T1 A5 KP997075
KS55 40 M MIXED
RACE
AIDS-KS YES UNKNOWN T1 U KP997076
KS56 25 F BLACK AIDS-KS YES 320 T0 B3 KP997077
KS57 36 M BLACK AIDS-KS YES 270 T1 A5 KP997078
KS58 58 F BLACK AIDS-KS YES 231 T0 B3 KP997079




N/A N/A N/A B1 KP997081
KS61 35 M BLACK AIDS-KS YES 61 T0 B2 KP997082
KS62 32 M BLACK AIDS-KS YES 133 T0 A5 KP997083
KS63 34 F BLACK AIDS-KS YES 77 T1 B3 KP997084
KS64 31 F BLACK AIDS-KS YES 99 T1 A5 KP997085
KS65 43 M WHITE AIDS-KS YES 50 T0 A4 KP997086
KS67 34 M BLACK AIDS-KS YES 547 T1 A5 KP997087
KS68 34 F BLACK AIDS-KS YES 10 T0 A5 KP997088
KS69 26 F BLACK AIDS-KS NO 110 T1 A5 KP997089
KS70 35 F BLACK AIDS-KS YES 138 T0 A5 KP997090
KS72 30 F MIXED
RACE
AIDS-KS YES 555 T1 A5 KP997091
KS73 24 F BLACK AIDS-KS YES 288 T1 A5 KP997092
KS74 51 M BLACK AIDS-KS YES UNKNOWN T1 A5 KP997093
KS76 31 F BLACK AIDS-KS YES 220 T0 B3 KP997094
KS77 49 M BLACK AIDS-KS YES 71 T1 B2 KP997095
KS78 37 M BLACK AIDS-KS YES UNKNOWN T0 B1 KP997096
KS79 42 M BLACK AIDS-KS YES 14 – A5 KP997097
KS80 41 M BLACK AFRICAN
ENDEMIC
N/A N/A N/A A5 KP997098
KS83 39 F MIXED AIDS-KS YES 163 T0 B3 KP997100
(Continued)
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and B are widespread in Africa [Cook et al., 1999;
Hayward, 1999; Meng et al., 1999; Zong et al., 1999;
Fouchard et al., 2000; Lacoste et al., 2000; Treurnicht
et al., 2002; Kajumbula et al., 2006]. The finding that
A5 was the predominant subtype is consistent with
that of Hayward and Zong [2007] but is different
from the finding of another South African study that
showed B2 as the predominant subtype [Treurnicht
et al., 2002]. This difference is quite likely due to the
small number of patients studied and subtyped by
Treurnicht et al., only 10 patients (8 black and 2 of
mixed of ancestry). Four of these 10 patients had
iatrogenic KS (3 B2, 1 A5), 5 patients were African
endemic KS (2 B2, 2 A5 and 1 novel B variant) and
1 had AIDS PEL (B2). In the current study, only one
patient had iatrogenic KS and could not be subtyped.
Zong and Hayward proposed that HHV8 is a
relatively old human virus that evolutionarily radi-
ated along with early human populations migrating
out of Africa, resulting in HHV8 genotypes that are
distributed along broad geographic and ethnic lines
[Hayward, 1999; Zong et al., 1999]. Cook and Zong
proposed that subtype B is the more ancient strain,
originating in Africa, and that A and C correspond to
European and Northern American HHV8 genotypes
[Cook et al., 1999; Zong et al., 1999]. The current
findings that all strains of subtype B (B1, B2, and
B3) are present in black patients or those of mixed
ancestry supports this proposal. Other studies have
reported that A5 is widespread throughout Africa,
and suggest an African origin for this genotype
[Lacoste et al., 2000]. According to Hayward et al.,
A5 may have been introduced by a single source from
Europe or North Africa into a B subtype genome in
ancestors of the Bantu people, which spread through
sub-Saharan Africa with the Bantu expansion from
West Africa about 4,000 years ago [Hayward and
Zong, 2007]. The term Bantu people is used to denote
ethnic groups in Africa who speak Bantu languages
and inhabit a geographical area extending from
Central to Southern Africa. The Bantu expansion
into South Africa reached KwaZulu-Natal by 300
A.D. and the Northern Province by 500 A.D, and may
account for the presence of A5 in South Africa. The
hypothesis of Hayward et al. to explain the distribu-
tion of A5 in Africa is that A5 evolved in Africa
through a rapid and recent aggressive spread
through recombinant events, augmented by the
strong selective advantage offered by the A5 allele
[Hayward, 1999]. In support of this theory, all
TABLE II. (Continued)




KS84 27 M BLACK AIDS-KS YES 313 T0 A5 KP997101
KS88 36 M BLACK AIDS-KS YES 220 T0 B1 KP997104
KS90 30 M BLACK AIDS-KS YES 130 – A5 KP997106
KS91 38 M BLACK AIDS-KS YES 129 T0 A5 KP997107
KS92 32 M BLACK AIDS-KS YES 539 T1 U KP997108
KS93 29 F BLACK AIDS-KS YES 256 – A5 KP997109
KS101 47 M BLACK AIDS-KS N 396 T1 A5 KP997110
KS103 36 M BLACK AIDS-KS YES 208 T0 A5 KP997111
KS104 29 M MIXED
RACE
AIDS-KS YES 149 T0 A1 KP997112
KS107 27 F BLACK AIDS-KS YES 40 T1 A5 KP997113
KS108 26 F BLACK AIDS-KS YES 15 – B2 KP997114
KS109 38 M BLACK AIDS-KS NO 129 T0 B1 KP997115
KS113 52 F BLACK AIDS-KS YES UNKNOWN T1 A5 KP997117
KS115 63 M BLACK AIDS-KS YES 250 T1 A5 KP997118
KS117 31 F BLACK AIDS-KS NO 1 T0 B2 KP997119
KS119 53 F BLACK AIDS-KS YES 69 T1 A5 KP997120
KS121 31 M BLACK AIDS-KS NO 403 T1 B1 KP997122
KS123 34 M BLACK AIDS-KS NO 225 T1 A5 KP997124
KS125 65 M BLACK AIDS-KS NO 339 T0 A5 KP997125
KS126 36 M BLACK AIDS-KS YES 83 T1 A5 KP997126
KS127 30 M BLACK AFRICAN
ENDEMIC
N/A N/A T0 A5 KP997127
KS130 47 F BLACK AIDS-KS YES 483 T1 B3 KP997128
KS131 35 M BLACK AIDS-KS NO 251 – B2 KP997129
KS132 26 M BLACK AIDS-KS YES 153 T0 B2 KP997130
KS136 41 M MIXED
RACE
AIDS-KS NO 174 – A1 KP997133
KS137 53 M MIXED
RACE
AIDS-KS YES UNKNOWN T1 U KP997134
KS138 38 M MIXED
RACE
AIDS-KS YES 56 T1 A5 KP997135
ARV, antiretroviral therapy; T1, tumor-associated edema or ulceration, nodular oral KS, visceral KS; T0, confined to skin and or lymph
nodes and/or non-nodular KS of the palate; N/A, not applicable; U, unclustered.
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subtype A5 typed to date are recombinant chimeras
in which a very small portion of the left hand side of
the genome (ORF-K1) is A-like, hence classified as
subtype A5, while the remainder is made up of the
African-specific B, as well as Q, R, and N subtypes
constant region genomes [Hayward and Zong, 2007].
However, many South African genomes with ancient
N type segments of presumed Khoisan or Xhosa
origin, are ORF-K1 subtype A5, suggesting that more
recent recombinant events occurred once Bantu
chimeric genomes interacted with Khoisan genomes
[Hayward and Zong, 2007].
According to Hayward and Zong, many South
African genomes contain a much greater degree of
variability in both the constant region and right hand
side of the genome [Hayward and Zong, 2007].
Treurnicht et al. [2002] reported the presence of B3/C2
ORF26 constant region subtypes in A5 ORF-K1
Fig. 2. Phylogenetic tree based on ORF-K1 coding region
constructed by applying the neighbor-joining method to a
matrix of pairwise distances estimated using the maximum
composite likelihood (MCL) approach from 86 samples and
other related reference strains obtained from GenBank
database. The numbers given at each node represent the
percentage bootstrap values (for 1,000 replications). Bootstrap
value numbers less than 60 are not shown in the figure. Isolates
that are circled are variants that did not cluster and are not
subtyped.
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subtypes in South Africa. This suggests the hypothesis
that the positive selective advantage of A5, may be as
a result of the recombinant chimera, and not necessa-
rily due to A5 alone. The prevalence of A5 in the
current study (43/87, 49%) is consistent with that of
53% found in 31 AIDS-KS patients in Uganda
[Kajumbula et al., 2006], and that of 40% found in 65
AIDS-KS patients in Zimbabwe [White et al., 2008],
and 47% (7/15) found in 15 South African KS patients
[Hayward and Zong, 2007]. European Subtypes A1 and
A4 were found only amongst whites and patients of
mixed ancestry, who were HIV positive. In our study,
none of the European subtypes were present in black
patients. This was also the case in Hayward and Zongs’
study where the only two A4 ORF-K1 subtypes were in
patients of Dutch descent [Hayward and Zong, 2007].
This supports the proposal that genetic subtypes of
HHV8 are distributed along geographic and ethnic
lines [Hayward, 1999; Zong et al., 1999, 2002]. South
Africa has a diverse population and factors such
as European and Asian colonization and human
migration in Africa and the resultant mixed ancestry
may account for the prevalence of the European
subtypes in the South African population.
Four of the patients (5%), all AIDS-KS patients
had viruses that failed to cluster with any of the
known subtypes and these viruses were termed
unclustered. This could be due to either recombina-
tion events between two existing subtypes or the
development of new evolving strains.
Controversy exists around the pathogenicity and
virulence of HHV8 subtype A. [Boralevi et al., 1998;
Hayward, 1999; Meng et al., 1999; Zong et al., 1999;
Lacoste et al., 2000; Mancuso et al., 2008; White
et al., 2008; Zhang et al., 2008]. In an Italian study,
subtype A has been linked with more rapidly pro-
gressing disease in classic KS [Mancuso et al., 2008].
Boralevi et al. reported that out of 40 HHV8 isolates
from French AIDS-KS cases evaluated, subtype A
was associated with more advanced disease, frequent
mucosal and/or visceral KS (63% in subtype A vs.
27% in subtype B, P< 0.05) and concluded that
subtype A displayed more aggressive pathogenicity
[Boralevi et al., 1998]. This was confirmed in a study
of 23 classic KS and 4 AIDS-KS cases by Zhang
et al., in Xinjang, China, that showed that HHV8
subtype A was associated with more frequent mu-
cosal lesions than subtype C [Zhang et al., 2008].
These data raise the question as to whether subtype
A has unique biological features which makes it more
pathogenic, and hence prognostically relevant.
In the present study, subtype A5 was found in
patients who presented with more extensive disease,
that is, more than 10 lesions. This suggests that A5
subtype may be associated with more extensive
disease and supports the findings of Mancuso,
Boralevi, and Zhang that subtype A may have more
aggressive characteristics of pathogenicity [Boralevi
et al., 1998; Mancuso et al., 2008; Zhang et al., 2008].
The current study describes the first reported obser-
vation of a possible association between subtype A5
and clinical presentation of KS, in particular more
extensive disease in AIDS-KS. However, additional












Oral mucosa 30 (35)
Trunk 50 (58)
Upper limb 45 (52)
Lower limb 70 (81)
Genitalia 6 (7)
Lymphoedema 42 (49)
Number of lesions at presentation
<10 lesions 24 (28)
>10 lesions 62 (72)
TABLE IV. Association of Human Herpes Virus 8 Subtypes With Extent of Kaposi’s Sarcoma
Unadjusted Adjusteda
Subtypes <10 lesions >10 lesions OR (95%CI) P-value OR (95%CI) P-value
A1 Neg 21 63 1 1
Pos 3 1 0.11 (0.11–1.16) 0.067 0.11 (0.01–1.48) 0.096
A4 Neg 23 62 1 1
Pos 1 0 – N/A – N/A
A5 Neg 16 28 1 1
Pos 8 34 2.42 (0.91–6.50) 0.078 3.13 (1.02–9.58) 0.046
B1 Neg 20 56 1 1
Pos 4 6 0.54 (0.14–2.10) 0.37 0.98 (0.15–6.52) 0.986
B2 Neg 18 52 1 1
Pos 6 10 0.58 (0.18–1.81) 0.347 0.49 (0.15–1.68) 0.258
B3 Neg 22 55 1 1
Pos 2 7 1.40 (0.27–7.27) 0.689 0.87 (0.13–5.63) 0.883
aLogistic regression model adjusted for age, sex, CD4 count, OR(95% CI)¼ odds ratio (95% confidence interval).
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larger studies are required in order to verify this
finding and correct for cohort-related biases. This
could have important implications on disease progno-
sis and determining therapeutic options and response
to treatment. More aggressive therapy, namely ART
with combined chemotherapy may be warranted in
AIDS-KS patients with subtype A5 at the onset of
disease.
An association between subtypes and clinico-
epidemiological forms of KS has been reported in
some studies [Gazouli et al., 2004; Ramos da Silva
et al., 2011], but not in others [Cook et al., 1999;
Meng et al., 1999; Zong et al., 1999; Lacoste et al.,
2000; White et al., 2008]. Most recently, da Silva
et al. reported that out of 50 KS patients evaluated
in Brazil, an elevated frequency of HHV8 subtype A
was found in HIV-positive patients (15/22; 68,2%).
Conversely, the majority of KS isolated from HIV-
negative patients had subtype C. The difference in
proportions between A and C subtypes within HIV-
positive and HIV-negative patients was statistically
significant (P¼ 0.026, Fisher’s exact test) [Ramos da
Silva et al., 2011]. Distribution of ORF-K1 variants
among classic and AIDS-KS in the United States
showed predominantly C subtypes in classic KS,
while AIDS-KS were predominantly subtype A, but
this was not statistically evaluated [Zong et al.,
2002]. Gazouli also suggested an association of
subtype A4 in AIDS-KS and A1 in classic KS in
Greece [Gazouli et al., 2004]. The present study found
a strong association between subtype A5 and extent
of disease in AIDS-KS, but not in African endemic
KS. However, this conclusion may be because the
African endemic group in the study consisted of only
five patients. In the present study, subtype A1 was
associated with a lower likelihood of lower limb
involvement. The lower limb is the typical site for
classic KS. However, in the current study A1 and A4
were all AIDS-KS patients. In addition, A1 and A4
were associated with a lower likelihood of poor risk
tumor extension, hence a better prognosis.
There were slightly more women than men in the
age group <35 years affected with KS, suggesting an
earlier age of presentation of KS in women, while
above 35 years, there were markedly more men
affected. This finding that KS occurs at an earlier
age in women compared to men, is consistent with a
study of 152 patients conducted in KwaZulu-Natal,
South Africa, as well as with smaller retrospective
studies conducted in Europe and United States
[Cooley et al., 1996; Nasti et al., 1999; Mosam et al.,
2008]. Reasons proposed for this early age of presen-
tation in women include that the risk for developing
female KS is closely related to the epidemiology of
the HIV. In KwaZulu-Natal, the age-specific distribu-
tion pattern for female KS [Mosam et al., 2008] was
essentially identical to the age specific distribution
pattern of HIV reported in an earlier study [Mosam
et al., 2008; Rollins et al., 2002]. Health-seeking
behavior and access to health care may also contrib-
ute to this finding. Women may have been exposed to
HIV testing during antenatal care, hence referred to
HIV treatment centers earlier resulting in earlier KS
identification.
There are several limitations to the current study.
A major limitation of this study is that only one
segment of HHV8 genome, ORF-K1, was subtyped. It
would have been more useful to evaluate the constant
region as well the right hand side of the genome,
especially with respect to recombinant genomes in
A5, as well as the greater degree of hypervariability
in the constant and RHS of South African genomes
[Hayward and Zong, 2007]. Hayward and Zong
address this aspect of only using one segment of the
genome to make conclusions about pathological corre-
lations [Hayward and Zong, 2007; Zong et al., 2007].
The interpretation of biological and pathological
correlations from one segment has to take into
account the geographical patterns, the frequency of
heterogeneity in the virus, and recombinant and
chimeric genomes [Zong et al., 2007]. However, if the
assumption is made based on the 14 South African
samples of Hayward and Zong that all of the South
African genomes are non A/C in the bulk center
blocks and non-M at the K15 right hand side of the
genome [Hayward and Zong, 2007], then one can
generalize from the ORF-K1 data alone. Any future
studies looking at correlations between ORF-K1 and
pathogenicity should take into account other poly-
morphic loci within the genome and the possibility of
recombinant genomes.
The morphological description of KS relied on
observer’s subjective documentation on body diagrams,
photographic records, and clinical records. However,
all the patients were seen by dermatologists of the
same department, making the morphological descrip-
tions more uniform. Complete ACTG staging was not
available for patients, and there was limited assess-
ment of visceral involvement. This was due to the
standard of care offered in the oncology unit which is
based on the tenant that treatment would remain
unchanged irrespective of visceral involvement.
Clinical data on the duration on ART in AIDS-KS
cases were not available, which may have impacted on
clinical presentation. Other potential confounding
variables that were not controlled for include disease
duration and whether on chemotherapy. Subtyping of







A1 0 (0) 3 (30) 1 (50) 4 <0.001
A4 0 (0) 0 (0) 1 (50) 1 0.023
A5 40 (56) 2 (20) 0 (0) 42 0.040
B1 9 (12) 1 (10) 0 (0) 10 1.000
B2 15 (94) 1 (6) 0 (0) 16 0.788
B3 8 (89) 1 (11) 0 (0) 9 1.000
Unclustered 2 (3) 2 (20) 0 (0) 4 0.092
Total 74 10 2 86
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ORF-K1 was only possible in 86 cases. Subtyping was
unsuccessful because of failure to PCR amplify the
DNA region combined with insufficient DNA. This is
consistent with previous studies, such as that of
Zhang, where only 22/27 could be successfully ampli-
fied, and that of White where only 65/171 could be
amplified due to insufficient DNA [White et al., 2008;
Zhang et al., 2008].
Language was used as proxy for ethnicity. This
may not be the most accurate measure of ethnicity,
but was the only means of assessing ethnicity in a
retrospective study. The findings that there was a
strong association between genetic subtypes and
ethnicity, strengthens the use of language as proxy
for ethnicity.
Variability within the ORF-K1 gene displays very
high nonsynonymous rates, with up to 85% of nucleo-
tide changes producing amino acid changes, implying
that a powerful biological selection process is involved
[Hayward and Zong, 2007; Zong et al., 1999]. The
advantage of the rapidity of evolution of ORF-K1
subtypes of HHV8 is yet to be elucidated, but may be
due to a need of the virus to evade the immune
system and establish persistent infection as described
in HHV6 [Lusso et al., 1995] or due to increasing the
pathogenicity and virulence of HHV8. Infection with
HHV8 may also potentially have an as yet unknown
evolutionary advantage to the human host as has
been postulated for EBV and HHV6 [Hesla et al.,
2013].
In summary, subtypes A5 and B were found to
predominate in South Africa, and are distributed
along broad ethnic lines. More extensive disease was
noted in AIDS-KS associated A5 subtype. A1 and A4
combined were associated with a lower likelihood of
poor risk tumor extension, and A1 with a lower
likelihood of lower limb involvement. Further re-
search is needed to confirm the proposal that A5 may
be a more pathogenic strain than subtype B in
Africa.
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ADDENDUM	  TO	  MANUSCRIPT	  AS	  REQUESTED	  BY	  EXAMINER	  
	  
ADDENDUM	  1:	  DETAIL	  ON	  4	  UNCLUSTERED	  SAMPLES	  
	  
Four	  samples	  did	  not	  cluster	  with	  any	  of	  the	  major	  subtypes	  and	  were	  labelled	  as	  
unknown/unclustered.	  These	  four	  samples,	  although	  unique,	  did	  have	  some	  features	  
suggesting	  a	  major	  subtype;	  KS92	  was	  B-­‐like,	  KS55	  and	  KS137	  were	  F-­‐like	  while	  KS11	  was	  A-­‐
like.	  	  
	  
ADDENDUM	  2:	  DETAIL	  ON	  B3	  
	  
The	  B3	  variant	   is	  distinguishable	   from	  other	  B	  variants	  by	  a	  motif	  at	   the	  beginning	  of	  VR2	  
(residues	  194-­‐198).	  Kajumbula	  et	  al	  identified	  two	  sequences	  that	  belonged	  to	  a	  new	  variant	  
which	   they	   called	   B3.	   These	   sequences	   clustered	   with	   previously	   identified	   B	   sequences	  
from	  Ugandan	   samples	   (Ugd1,	   Ugd19,	   Ugd7,	   Ugd2,	   Ugd21	   and	  Ugd26)	   [Kajumbula	   et	   al.,	  
2006,	  Kakoola	  et	  al.,	  2001].	  	  
In	  our	  study,	  we	  have	  used	  AY042940	  (Ugd26)	  as	  a	  reference	  sequence	  for	  the	  B3	  variant.	  
This	  is	  comparable	  to	  White	  et	  al	  2009	  who	  used	  Ugd26	  (AY042940)	  as	  well	  as	  the	  other	  5	  
sequences	   (Ugd1,	   Ugd19,	   Ugd7,	   Ugd2	   and	  Ugd21)	   as	   B3	   references	   in	   their	   phylogenetic	  
analysis	   [White	   et	   al.,	   2009].	   Olp	   et	   al	   used	   AY042941	   (Ugd19)	   as	   their	   B3	   reference	  
sequence	  which	   clustered	  with	   Ugd26	   [Olp	   et	   al.,	   2015].	   Hence	   the	   B3	   sequences	   in	   this	  
study,	  cluster	  with	  the	  B3	  sequences	  of	  Kakoola,	  Kajumbula,	  White	  and	  Olp	  [Kajumbula	  et	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CHAPTER	  3:	  APPENDICES	  
APPENDIX	  1	  
KARNOFSKY	  SCORE	  [Karnofsky	  et	  al:	  Cancer	  1:64,	  1948] 
Able	  to	  carry	  on	  normal	  activity;	  no	  special	  
care	  is	  needed	  
	  
100	  Normal;	  no	  evidence	  of	  disease	  
90	  Able	  to	  carry	  on	  activity;	  minor	  signs	  or	  
symptoms	  of	  disease	  
80	  Normal	  activity	  with	  effort;	  some	  signs	  
and	  symptoms	  of	  disease	  
Unable	  to	  work;	  able	  to	  live	  at	  home	  and	  
care	  for	  most	  personal	  needs;	  a	  varying	  
amount	  of	  assistance	  is	  needed	  
	  
70	  Cares	  for	  self;	  unable	  to	  carry	  on	  normal	  
activity	  or	  to	  do	  active	  work	  
60	  Requires	  occasional	  assistance	  but	  is	  
able	  to	  care	  for	  most	  needs	  
50	  Requires	  considerable	  assistance	  and	  
frequent	  medical	  care	  
Unable	  to	  care	  for	  self;	  requires	  equivalent	  
of	  institutional	  or	  hospital	  care;	  disease	  
may	  be	  progressing	  rapidly	  
40	  Disabled;	  requires	  special	  care	  and	  
assistance	  
30	  Severely	  disabled;	  hospitalization	  is	  
indicated	  although	  death	  not	  imminent	  
20	  Very	  sick;	  hospitalization	  necessary;	  
active	  supportive	  treatment	  is	  
necessary	  
10	  Moribund,	  fatal	  processed	  progressing	  
rapidly	  
0	  Dead	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APPENDIX	  2	  
	  
Supplementary	  Table	  S1:	  Correlation	  of	  subtypes	  with	  number	  of	  lesions  
	   >10	  (%)	   <10	  (%)	   Total	   P	  value	  
A1	   1	  (2)	   3	  (13)	   4	   0,064	  
A4	   0	  (0)	   1	  (4)	   1	   0,279	  
A5	   34	  (55)	   8	  (33)	   42	   0.074	  
	  	  	  AIDS-­‐KS	  
	  	  	  African	  endemic	  
32	  (52)	   6	  (25)	   38	   0,050	  
2	  (3)	   2	  (8)	   4	   0,600	  











Unclustered	   4	  (6)	   0	  (0)	   4	   0,263	  
Total	  	   62	   24	   86	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PATIENT`S)INFORMATION)SHEET))
AND)CONSENT)FORM)
) ) ) ) ) ) PAGE)1)
                                                                                                               





















herpes) virus) (KSHV)) which) is) also) named) human) herpesvirusR8) (HHVR8).))
This) disease) is) present) in) Africa) and) in) other) parts) of) the)world) including)
USA)and)Europe.) ) )However,)only) the)viruses) isolated) from)patients) in) the)
USA)and)Europe)have)been)studied.)))In)this)project)we)intend)to)study)the)
Kaposi’s) sarcomaRassociated) herpes) virus) present) in) South) African)
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PATIENT`S)INFORMATION)SHEET))
AND)CONSENT)FORM)
) ) ) ) ) ) PAGE)2)
                                                                                                               




out) of) the) tumour.) They) will) first) give) you) an) injection) that) may) sting) to)
anaesthetise)the)tumour)area.)The)injection)is)like)the)one)the)dentist)uses.)




will) slowly)start) to) feel)mild)soreness) in) the)area)as) the)anaesthetic)wears)













in) so) far) as) they) are) reflected) in) the) study) will) be) reported/disclosed) (in) a)






Your) decision) whether) or) not) to) participate) will) not) prejudice) your) future)
relations) and) with) the) hospital/clinic) or) your) doctor.) ) If) you) decide) to)
participate,)you)are)free)to)withdraw)consent)at)any)time)and)such)withdrawal)
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PATIENT`S)INFORMATION)SHEET))
AND)CONSENT)FORM)
) ) ) ) ) ) PAGE)3)
                                                                                                               
       
 
 





information) leaflet) about) the) study.) I) fully) understand) the) reasons) why) the)
study)is)being)done.)I)am)aware)that)a)sample)of)my)tumour)will)be)taken)for)
purposes)of)this)study.))
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